{"content":"<li class=\"n-box-item date-title\" data-end=\"1574312399\" data-start=\"1574226000\" data-txt=\"Monday, December 23, 2019\">Wednesday, November 20, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3521080\" data-ts=\"1574294736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPTN\" target=\"_blank\">OPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521080-optinoseminus-9_7-on-report-of-offering-14_6-discount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OptiNose -9.7% on report of offering at 14.6% discount</a></h4><ul>   <li>OptiNose (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTN' title='OptiNose, Inc.'>OPTN</a>) is <font color=\"red\">off 9.7%</font> postmarket after a report that an <a href=\"https://seekingalpha.com/news/3520967-optinose-readies-equity-offering\" target=\"_blank\">equity offering</a> (from the company and shareholders) will amount to $50M in shares.</li>    <li>Those shares will come at $9.75 each, a 14.6% discount to the close, Bloomberg reports.</li>    <li>The offering is coming via Jefferies, Cowen, Piper Jaffray and BMO.</li>    <li>Proceeds are targeted toward working capital and general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521080\" data-linked=\"OptiNose -9.7% on report of offering at 14.6% discount\" data-tweet=\"$OPTN - OptiNose -9.7% on report of offering at 14.6% discount https://seekingalpha.com/news/3521080-optinoseminus-9_7-on-report-of-offering-14_6-discount?source=tweet\" data-url=\"https://seekingalpha.com/news/3521080-optinoseminus-9_7-on-report-of-offering-14_6-discount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521079\" data-ts=\"1574294415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521079-uberplus-1_5-ceo-buys-6_69m-worth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber +1.5% as CEO buys $6.69M worth</a></h4><ul>   <li>Uber (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) is <font color=\"green\">up 1.5%</font> after hours following the disclosure that CEO Dara Khosrowshahi <a href=\"https://seekingalpha.com/filing/4707556\" target=\"_blank\">bought 250,000 shares</a> this week.</li>    <li>He purchased that amount at an average price of $26.75 on Monday, making for a total purchase of just under $6.69M worth.</li>    <li>The purchase brings his beneficial direct ownership to 1,530,939 shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521079\" data-linked=\"Uber +1.5% as CEO buys $6.69M worth\" data-tweet=\"$UBER - Uber +1.5% as CEO buys $6.69M worth https://seekingalpha.com/news/3521079-uberplus-1_5-ceo-buys-6_69m-worth?source=tweet\" data-url=\"https://seekingalpha.com/news/3521079-uberplus-1_5-ceo-buys-6_69m-worth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521077\" data-ts=\"1574293934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521077-karuna-therapeuticsplus-1_5-wedbush-raises-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karuna Therapeutics +1.5% as Wedbush raises target</a></h4><ul>   <li>Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) is regaining some ground after hours, <font color=\"green\">up 1.5%</font> postmarket after Wedbush boosted its price target.</li>    <li>Shares had <font color=\"red\">fallen 12.1%</font> during the regular session today.</li>    <li>Wedbush raised its target to $134 from $38, an above-average target now implying 23% upside.</li>    <li>Overall, the <a href=\"https://seekingalpha.com/symbol/KRTX/ratings/sell-side-ratings\" target=\"_blank\">Street is Very Bullish</a> on the stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521077\" data-linked=\"Karuna Therapeutics +1.5% as Wedbush raises target\" data-tweet=\"$KRTX - Karuna Therapeutics +1.5% as Wedbush raises target https://seekingalpha.com/news/3521077-karuna-therapeuticsplus-1_5-wedbush-raises-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3521077-karuna-therapeuticsplus-1_5-wedbush-raises-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521066\" data-ts=\"1574290726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBSE\" target=\"_blank\">NBSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521066-neubaseplus-5_2-oppenheimer-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuBase +5.2% as Oppenheimer starts at Outperform</a></h4><ul>   <li>NeuBase Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBSE' title='NeuBase Therapeutics, Inc.'>NBSE</a>) is building on a strong gain today, <font color=\"green\">up 5.2%</font> after hours as it gets an initiation at Outperform by Oppenheimer.</li>    <li>The firm set its price target to $14 (in line with other Street targets), implying $122 upside from today's close.</li>    <li>NeuBase closed <font color=\"green\">up 25.2%</font> today in apparent <a href=\"https://seekingalpha.com/news/3520944-neubase-therapeutics-30-percent-alnylam-approval\" target=\"_blank\">sympathy with Alnylam</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>), which has similar technology and saw FDA approval of its Givlaari for acute hepatic porphyria.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3521066\" data-linked=\"NeuBase +5.2% as Oppenheimer starts at Outperform\" data-tweet=\"$NBSE $NBSE $ALNY - NeuBase +5.2% as Oppenheimer starts at Outperform https://seekingalpha.com/news/3521066-neubaseplus-5_2-oppenheimer-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3521066-neubaseplus-5_2-oppenheimer-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521059\" data-ts=\"1574289221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521059-nuance-communications-leads-after-hour-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuance Communications leads after hour gainers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/NUAN' title='Nuance Communications, Inc.'>NUAN</a> <font color=\"green\">+8.3%</font>. <a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a> <font color=\"green\">+3.7%</font>. <a href='https://seekingalpha.com/symbol/NNBR' title='NN, Inc.'>NNBR</a> <font color=\"green\">+3.7%</font>. <a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a> <font color=\"green\">+3.4%</font>. <a href='https://seekingalpha.com/symbol/JACK' title='Jack in the Box Inc.'>JACK</a> <font color=\"green\">+2.9%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/OPTN' title='OptiNose, Inc.'>OPTN</a> <font color=\"red\">-10.4%</font>. <a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a> <font color=\"red\">-8.7%. </font><a href='https://seekingalpha.com/symbol/CUB' title='Cubic Corporation'>CUB</a> <font color=\"red\">-6.3%</font>. <a href='https://seekingalpha.com/symbol/ACP' title='Aberdeen Income Credit Strategies Fund'>ACP</a> <font color=\"red\">-6.0%</font>. <a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a> <font color=\"red\">-3.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521059\" data-linked=\"Nuance Communications leads after hour gainers\" data-tweet=\"$NUAN $KRTX $NNBR - Nuance Communications leads after hour gainers https://seekingalpha.com/news/3521059-nuance-communications-leads-after-hour-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521059-nuance-communications-leads-after-hour-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521041\" data-ts=\"1574287119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521041-neon-up-19-after-hours-on-restructuring-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neon up 19% after hours on restructuring plan</a></h4><ul><li>Nano cap Neon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics, Inc.'>NTGN</a>) jumps <font color=\"green\">19%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17706451-neon-therapeutics-announces-new-strategic-focus-novel-t-cell-programs\" target=\"_blank\">announced restructuring</a> aimed at sharpening its focus on developing its novel neoantigen-based T cell programs.</li><li>The initiative will involve the elimination of ~24% of its workforce, the avoidance of new spending on its cancer vaccine programs (NEO-PV-01 and NEO-SV-01) and the termination of enrollment in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03597282?lead=neon+therapeutics&amp;draw=2&amp;rank=1\" target=\"_blank\">NT-003 study</a> assessing NEO-PV-01 in metastatic melanoma. Follow-up will continue in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03380871?lead=neon+therapeutics&amp;draw=2&amp;rank=2\" target=\"_blank\">NT-002 trial</a> of NEO-PV-01 in first-line lung cancer.</li><li>Concurrently, the company will explore strategic alternatives, adding that its current quick asset balance should be sufficient to fund operations into Q3 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521041\" data-linked=\"Neon up 19% after hours on restructuring plan\" data-tweet=\"$NTGN - Neon up 19% after hours on restructuring plan https://seekingalpha.com/news/3521041-neon-up-19-after-hours-on-restructuring-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3521041-neon-up-19-after-hours-on-restructuring-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521039\" data-ts=\"1574286862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521039-tiffanyplus-4_7-on-report-lvmh-boosts-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tiffany +4.7% on report LVMH boosts offer</a></h4><ul>   <li>Tiffany (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) is <font color=\"green\">up 4.7%</font> postmarket on a report from Reuters that LVMH (<a href='https://seekingalpha.com/symbol/LVMHF' title='LVMH Moët Hennessy - Louis Vuitton, Société Européenne'>OTCPK:LVMHF</a>) has <a href=\"https://www.reuters.com/article/us-tiffany-m-a-lvmh-exclusive/exclusive-lvmh-gets-access-to-tiffanys-books-after-it-raises-offer-sources-idUSKBN1XU2PV\" target=\"_blank\">raised its offer</a> for the company to $130/share, and got access to Tiffany's books.</li><li>The bid hike persuaded Tiffany to provide confidential due diligence, according to the report.</li>    <li>Tiffany shares closed today at $123.33; the new reported offer marks a 5.4% premium.</li>    <li>Meanwhile, the former CEO of Barney's is moving to Tiffany's newly created <a href=\"https://pagesix.com/2019/11/20/former-barneys-ceo-headed-to-tiffany-co/?_ga=2.66481453.2060698788.1574083777-946445274.1524685780\" target=\"_blank\">chief brand officer position</a>, the <i>New York Post</i> reports.</li>    <li>Daniella Vitale stepped down from bankrupt Barney's after it was bought by Authentic Brands.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521039\" data-linked=\"Tiffany +4.7% on report LVMH boosts offer\" data-tweet=\"$TIF $LVMHF - Tiffany +4.7% on report LVMH boosts offer https://seekingalpha.com/news/3521039-tiffanyplus-4_7-on-report-lvmh-boosts-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3521039-tiffanyplus-4_7-on-report-lvmh-boosts-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521030\" data-ts=\"1574286246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUB\" target=\"_blank\">CUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521030-cubicminus-3_6-profits-miss-despite-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cubic -3.6% as profits miss despite revenue growth</a></h4><ul>   <li>Cubic (NYSE:<a href='https://seekingalpha.com/symbol/CUB' title='Cubic Corporation'>CUB</a>) has <font color=\"red\">slipped 3.6%</font> postmarket after a mixed report from its <a href=\"https://seekingalpha.com/news/3520976-cubic-eps-misses-0_08-beats-revenue\" target=\"_blank\">fiscal Q4 earnings</a>, where it topped revenue expectations with double-digit gains but adjusted profits fell short alongside a higher effective tax rate.</li>    <li>The company also announced deals to acquire the remaining stakes in Pixia and Delerrok after beginning to build stakes in those companies during fiscal 2018 and 2019.</li>    <li>Revenues rose 24% to $471.2M, and operating income jumped to $58.6M from $27.7M with the revenue gain and lower SG&amp;A expenses.</li>    <li>EBITDA rose 56%, to $76.6M.</li>    <li>Net income from continuing operations rose to $41.6M from $22M.</li>    <li>Cubic has a purchase agreement to buy the remaining 80% of Pixia for $200M (due for closing in February) and one to buy the remaining 82.5% of Delerrok (due for closing in December).</li>    <li>Cash from continuing operations was $50.8M; adjusted free cash flow was $52.1M (up from $36.4M).</li>    <li><a href=\"https://event.on24.com/wcc/r/2120553/3691CBEAF610547A9A9C5CA855C2ACA2\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17706457-cubic-reports-record-fourth-quarter-record-fiscal-2019-sales-adjusted-ebitda-provides-fiscal\" target=\"_blank\">Press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521030\" data-linked=\"Cubic -3.6% as profits miss despite revenue growth\" data-tweet=\"$CUB - Cubic -3.6% as profits miss despite revenue growth https://seekingalpha.com/news/3521030-cubicminus-3_6-profits-miss-despite-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3521030-cubicminus-3_6-profits-miss-despite-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521019\" data-ts=\"1574285593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521019-tonix-pharma-up-12-after-hours-on-advancement-of-tnxminus-102-sl-in-aud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD</a></h4><ul><li>Based on FDA feedback from a meeting, Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <a href=\"https://seekingalpha.com/pr/17706454-tonix-pharmaceuticals-completes-pre-ind-meeting-fda-tnxminus-102-sl-clinical-candidate\" target=\"_blank\">plans to file an IND</a> next quarter for a Phase 2 proof-of-concept study evaluating TNX-102 SL, branded as Tonmya, for the treatment of alcohol abuse disorder &#40;AUD&#41;.</li><li>The company says it has active INDs for the candidate in three other areas: post-traumatic stress disorder, fibromyalgia and Alzheimer's disease-related agitation.</li><li>TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption.</li><li>Shares up <font color=\"green\">12%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521019\" data-linked=\"Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD\" data-tweet=\"$TNXP - Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD https://seekingalpha.com/news/3521019-tonix-pharma-up-12-after-hours-on-advancement-of-tnxminus-102-sl-in-aud?source=tweet\" data-url=\"https://seekingalpha.com/news/3521019-tonix-pharma-up-12-after-hours-on-advancement-of-tnxminus-102-sl-in-aud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521012\" data-ts=\"1574285185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUAN\" target=\"_blank\">NUAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521012-nuanceplus-5_7-after-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuance +5.7% after Q4 beat</a></h4><ul>   <li>Nuance Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/NUAN' title='Nuance Communications, Inc.'>NUAN</a>) is <font color=\"green\">up 5.7%</font> after hours following a beat on top and bottom lines in its <a href=\"https://seekingalpha.com/news/3520973-nuance-communications-eps-beats-0_06-beats-revenue\" target=\"_blank\">fiscal Q4 report</a>.</li>    <li>Revenue grew 1.5% on a comparative basis to $489.3M (on ASC 605 standard).</li>    <li>Comparing results for continuing operations (after the sale of the Imaging business), organic revenue growth rose 2% Y/Y. Recurring revenue rose 650 basis points.</li>    <li>Operating margin went positive at 9.2%, vs. a year-go -1.7% (non-GAAP operating margin dipped to 28.3% from 29.4%).</li>    <li>And net income ticked up to $98.3M from $96M on a non-GAAP basis.</li>    <li>Operating cash flows were $104.2M, down from a year-ago's $134.8M.</li>    <li><a href=\"https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;referrer=https%3A%2F%2Finvestors.nuance.com%2Finvestors%2Fevents-and-presentations%2Fevent-details%2F2019%2FNuance-FY19-and-Q4-results-conference-call%2Fdefault.aspx&amp;eventid=2078811&amp;sessionid=1&amp;key=3EB2FE97A644464A3BDA4436E3F626A4&amp;regTag=&amp;sourcepage=register\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17706421-nuance-announces-fourth-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521012\" data-linked=\"Nuance +5.7% after Q4 beat\" data-tweet=\"$NUAN - Nuance +5.7% after Q4 beat https://seekingalpha.com/news/3521012-nuanceplus-5_7-after-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3521012-nuanceplus-5_7-after-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521009\" data-ts=\"1574285061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENLV\" target=\"_blank\">ENLV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521009-enlivex-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enlivex readies equity offering</a></h4><ul><li>Enlivex Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ENLV' title='Enlivex Therapeutics Ltd.'>ENLV</a>) initiates a <a href=\"https://seekingalpha.com/pr/17706469-enlivex-therapeutics-ltd-announces-proposed-offering-ordinary-shares\" target=\"_blank\">public offering</a> of ordinary shares. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521009\" data-linked=\"Enlivex readies equity offering\" data-tweet=\"$ENLV - Enlivex readies equity offering https://seekingalpha.com/news/3521009-enlivex-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3521009-enlivex-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521008\" data-ts=\"1574285008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521008-l-brands-pares-loss-after-earnings-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands pares loss after earnings drop</a></h4><ul><li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>) shoots <font color=\"green\">up 1.55%</font> in AH trading, despite the retailer slightly missing Q3 estimates.</li><li>Investors may be latching on to L Brands' Q4 profit guidance, which came in slightly ahead of expectations ($2.00 vs. $1.98 consensus).</li><li>Shares of L Brands were <font color=\"red\">down 7.22%</font> during the regular session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520996-l-brands-eps-misses-0_02-misses-revenue\" target=\"_blank\">L Brands EPS misses by $0.02, misses on revenue</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3521008\" data-linked=\"L Brands pares loss after earnings drop\" data-tweet=\"$LB - L Brands pares loss after earnings drop https://seekingalpha.com/news/3521008-l-brands-pares-loss-after-earnings-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3521008-l-brands-pares-loss-after-earnings-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521005\" data-ts=\"1574284954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTEM\" target=\"_blank\">MTEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521005-molecular-launches-equity-offering-shares-down-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molecular launches equity offering; shares down 6% after hours</a></h4><ul><li>Molecular Templates (NASDAQ:<a href='https://seekingalpha.com/symbol/MTEM' title='Molecular Templates, Inc.'>MTEM</a>) slips <font color=\"red\">6%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17706419-molecular-templates-inc-announces-proposed-public-equity-offering\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521005\" data-linked=\"Molecular launches equity offering; shares down 6% after hours\" data-tweet=\"$MTEM - Molecular launches equity offering; shares down 6% after hours https://seekingalpha.com/news/3521005-molecular-launches-equity-offering-shares-down-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3521005-molecular-launches-equity-offering-shares-down-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520996\" data-ts=\"1574284623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520996-l-brands-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands EPS in-line, misses on revenue</a></h4><ul><li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>): Q3 Non-GAAP EPS of $0.02 in-line; GAAP EPS of -$0.91.</li><li>Revenue of $2.68B (-3.2% Y/Y) <font color=\"red\">misses by $10M</font>.</li><li>Shares <font color=\"green\">+4.7%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17706486-l-brands-reports-third-quarter-2019-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520996\" data-linked=\"L Brands EPS in-line, misses on revenue\" data-tweet=\"$LB - L Brands EPS in-line, misses on revenue https://seekingalpha.com/news/3520996-l-brands-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520996-l-brands-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520985\" data-ts=\"1574284444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520985-jack-in-boxplus-3-after-ebitda-impresses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jack In The Box +3% after EBITDA impresses</a></h4><ul> <li>Jack in the Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack in the Box Inc.'>JACK</a>) reports company comparable sales increased 3.0% in FQ4 vs. +2.9% consensus. Company same-store sales rose 3.5%, driven higher by average check growth of 2.8%.</li> <li>Adjusted EBITDA was reported at $66.9M vs. $54.0M a year ago.</li>   <li>Restaurant-level EBITDA fell 190 bps to 24.2% of sales vs. 25.7% consensus. The drop was attributed to wage and commodity inflation.</li>   <li>The board approved another $100M in buyback firepower.</li> <li>Looking ahead, Jack in the Box expects adjusted EBITDA to land in the range of $265M to $275M vs. $260M to $270M prior view and $262M consensus.</li><li>JACK <font color=\"green\">+3.44%</font> AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520975-jack-box-eps-misses-0_01-misses-revenue\" target=\"_blank\">Jack In The Box EPS misses by $0.01, misses on revenue</a> (Nov. 20)</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3520985\" data-linked=\"Jack In The Box +3% after EBITDA impresses\" data-tweet=\"$JACK - Jack In The Box +3% after EBITDA impresses https://seekingalpha.com/news/3520985-jack-in-boxplus-3-after-ebitda-impresses?source=tweet\" data-url=\"https://seekingalpha.com/news/3520985-jack-in-boxplus-3-after-ebitda-impresses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520980\" data-ts=\"1574284201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONO\" target=\"_blank\">SONO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520980-sonos-eps-misses-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonos EPS misses by $0.06, beats on revenue</a></h4><ul><li>Sonos (NASDAQ:<a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a>): Q4 GAAP EPS of -$0.28 <font color=\"red\">misses by $0.06</font>.</li><li>Revenue of $294.16M (+7.8% Y/Y) <font color=\"green\">beats by $5.11M</font>.</li><li>Shares <font color=\"green\">+4.54%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17706446-sonos-reports-record-fiscal-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520980\" data-linked=\"Sonos EPS misses by $0.06, beats on revenue\" data-tweet=\"$SONO - Sonos EPS misses by $0.06, beats on revenue https://seekingalpha.com/news/3520980-sonos-eps-misses-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520980-sonos-eps-misses-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520973\" data-ts=\"1574283981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUAN\" target=\"_blank\">NUAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520973-nuance-communications-eps-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuance Communications EPS beats by $0.06, beats on revenue</a></h4><ul><li>Nuance Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/NUAN' title='Nuance Communications, Inc.'>NUAN</a>): Q4 Non-GAAP EPS of $0.34 <font color=\"green\">beats by $0.06</font>; GAAP EPS of $0.42 <font color=\"green\">beats by $0.41</font>.</li><li>Revenue of $489.33M (+1.5% Y/Y) <font color=\"green\">beats by $3.2M</font>.</li><li>Shares <font color=\"green\">+4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17706421-nuance-announces-fourth-quarter-fiscal-year-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520973\" data-linked=\"Nuance Communications EPS beats by $0.06, beats on revenue\" data-tweet=\"$NUAN - Nuance Communications EPS beats by $0.06, beats on revenue https://seekingalpha.com/news/3520973-nuance-communications-eps-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520973-nuance-communications-eps-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520967\" data-ts=\"1574283806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPTN\" target=\"_blank\">OPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520967-optinose-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OptiNose readies equity offering</a></h4><ul><li>OptiNose (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTN' title='OptiNose, Inc.'>OPTN</a>) launches a <a href=\"https://seekingalpha.com/pr/17706404-optinose-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520967\" data-linked=\"OptiNose readies equity offering\" data-tweet=\"$OPTN - OptiNose readies equity offering https://seekingalpha.com/news/3520967-optinose-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3520967-optinose-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520959\" data-ts=\"1574283151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KZIA\" target=\"_blank\">KZIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520959-kazia-therapeutics-up-83\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kazia Therapeutics up 83%</a></h4><ul><li>Ultra-thinly traded nano cap Kazia Therapeutics (<a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Limited'>KZIA</a> <font color=\"green\">+82.6%</font>) is up on a whopping 171x surge in volume, albeit on turnover of only 740K shares.</li><li>An abstract on a Phase 2 clinical trial evaluating lead candidate <a href=\"https://www.kaziatherapeutics.com/researchpipeline/GDC-0084\" target=\"_blank\">GDC-0084</a> in glioblastoma is being presented this week at the Society for Neuro-Oncology Annual Meeting in Phoenix.</li><li>An abstract on a study assessing GDC-0084 in breast cancer brain metastases will be presented at the San Antonio Breast Cancer Symposium next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520959\" data-linked=\"Kazia Therapeutics up 83%\" data-tweet=\"$KZIA - Kazia Therapeutics up 83% https://seekingalpha.com/news/3520959-kazia-therapeutics-up-83?source=tweet\" data-url=\"https://seekingalpha.com/news/3520959-kazia-therapeutics-up-83\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520958\" data-ts=\"1574282301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWD\" target=\"_blank\">WWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520958-woodward-downgraded-barrington-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Woodward downgraded at Barrington on valuation</a></h4><ul><li>Woodward (<a href='https://seekingalpha.com/symbol/WWD' title='Woodward, Inc.'>WWD</a> <font color='red'>-3.6%</font>) tumbles after Barrington Research <a href=\"https://thefly.com/thestreet/realmoney/index.php/WWDid2996729/WWD-Woodward-downgraded-to-Market-Perform-from-Outperform-at-Barrington\" target=\"_blank\">downgrades</a> shares to Market Perform from  Outperform without a price target, citing valuation and the company's \"mixed\" FQ4 results.</li><li>Barrington's Chris Howe says he continues to expect consistent revenue and earnings performance in WWD's aerospace segment, but with positives from the L'Orange addition already considered, he says he is only \"cautiously optimistic\" on the company's industrial segment due to  slowing economic growth, China trade headwinds and softening oil and gas  investments.</li><li>WWD's average <a href=\"https://seekingalpha.com/symbol/WWD/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while its <a href=\"https://seekingalpha.com/symbol/WWD/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520958\" data-linked=\"Woodward downgraded at Barrington on valuation\" data-tweet=\"$WWD - Woodward downgraded at Barrington on valuation https://seekingalpha.com/news/3520958-woodward-downgraded-barrington-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3520958-woodward-downgraded-barrington-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520949\" data-ts=\"1574280194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520949-polar-power-and-intelsat-among-tech-gainers-professional-diversity-network-and-qudian-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Polar Power and Intelsat among Tech gainers; Professional Diversity Network and Qudian among losers</a></h4><ul><li><b>Gainers: </b>Polar Power (NASDAQ:<a href='https://seekingalpha.com/symbol/POLA' title='Polar Power, Inc.'>POLA</a>) <font color=\"green\">+17%</font>. Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"green\">+15%</font>. My Size (NASDAQ:<a href='https://seekingalpha.com/symbol/MYSZ' title='My Size, Inc.'>MYSZ</a>) <font color=\"green\">+14%</font>. Net Element (NASDAQ:<a href='https://seekingalpha.com/symbol/NETE' title='Net Element, Inc.'>NETE</a>) <font color=\"green\">+9%</font>. Gridsum (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Professional Diversity Network (NASDAQ:<a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network, Inc.'>IPDN</a>) <font color=\"red\">-23%</font>. Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>) <font color=\"red\">-19%</font>. Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-13%</font>. Super League Gaming (NASDAQ:<a href='https://seekingalpha.com/symbol/SLGG' title='Super League Gaming, Inc.'>SLGG</a>) <font color=\"red\">-11%</font>. SunPower (NASDAQ:<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520949\" data-linked=\"Polar Power and Intelsat among Tech gainers; Professional Diversity Network and Qudian among losers\" data-tweet=\"$POLA $I $MYSZ - Polar Power and Intelsat among Tech gainers; Professional Diversity Network and Qudian among losers https://seekingalpha.com/news/3520949-polar-power-and-intelsat-among-tech-gainers-professional-diversity-network-and-qudian-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3520949-polar-power-and-intelsat-among-tech-gainers-professional-diversity-network-and-qudian-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520944\" data-ts=\"1574279820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBSE\" target=\"_blank\">NBSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520944-neubase-therapeutics-up-30-on-alnylam-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuBase Therapeutics up 30% on Alnylam approval</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3520900-fda-oks-alnylams-givosiran-ahp\" target=\"_blank\">FDA earlier approved</a> Alnylam's (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) Givlaari for acute hepatic porphyria. It's reported to be priced at $575K annually.</li><li>NeuBase (<a href='https://seekingalpha.com/symbol/NBSE' title='NeuBase Therapeutics, Inc.'>NBSE</a> <font color=\"green\">+30.7%</font>) has similar technology. David Einhorn's Greenlight Capital (<a href='https://seekingalpha.com/symbol/GLRE' title='Greenlight Capital Re, Ltd.'>GLRE</a> <font color=\"red\">-1.9%</font>) earlier this year <a href=\"https://twitter.com/yvsx/status/1149680896880066560\" target=\"_blank\">reported a stake</a> in the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520944\" data-linked=\"NeuBase Therapeutics up 30% on Alnylam approval\" data-tweet=\"$NBSE $GLRE $ALNY - NeuBase Therapeutics up 30% on Alnylam approval https://seekingalpha.com/news/3520944-neubase-therapeutics-up-30-on-alnylam-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3520944-neubase-therapeutics-up-30-on-alnylam-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520943\" data-ts=\"1574279469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAYC\" target=\"_blank\">PAYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520943-paycomplus-7_8-rbc-praises-price-retention-power\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paycom +7.8% as RBC praises price/retention power</a></h4><ul>   <li>Paycom Software (NYSE:<a href='https://seekingalpha.com/symbol/PAYC' title='Paycom Software, Inc.'>PAYC</a>) has <font color=\"green\">risen 7.8%</font> against a down market today after RBC Capital Markets upgraded the stock to Outperform after a meeting with management.</li>    <li>The firm came out of that with more confidence in the ability to \"realize price, improve retention, and drive a long runway of continued market disruption,\" writes analyst Alex Zukin.</li>    <li>He's raised the price target to $278 (near a Street high) from $230, now implying 8% upside.</li>    <li>Seeking Alpha authors are <a href=\"https://seekingalpha.com/symbol/PAYC/ratings/author-ratings\" target=\"_blank\">Neutral on the stock</a>, and it has a <a href=\"https://seekingalpha.com/symbol/PAYC/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520943\" data-linked=\"Paycom +7.8% as RBC praises price/retention power\" data-tweet=\"$PAYC - Paycom +7.8% as RBC praises price/retention power https://seekingalpha.com/news/3520943-paycomplus-7_8-rbc-praises-price-retention-power?source=tweet\" data-url=\"https://seekingalpha.com/news/3520943-paycomplus-7_8-rbc-praises-price-retention-power\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520942\" data-ts=\"1574279184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLB\" target=\"_blank\">SLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520942-schlumberger-halliburton-set-to-rebound-deutsche-bank-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schlumberger, Halliburton set to rebound, Deutsche Bank analyst says</a></h4><ul><li>Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color=\"green\">+4.7%</font>) reclaims its 50-day moving average after Tudor Pickering <a href=\"https://thefly.com/thestreet/realmoney/index.php/SLBid2996829/SLB-Schlumberger-upgraded-to-Buy-from-Sell-at-Tudor-Pickering\" target=\"_blank\">double-upgrades shares to Buy</a> from Sell with a $40 price target and Deutsche Bank <a href=\"https://www.barrons.com/articles/halliburton-and-schlumberger-stock-poised-to-rebound-analyst-says-51574265842\" target=\"_blank\">initiates coverage with a Buy rating</a> and $42 target.</li><li>Deutsche Bank's Chris Snyder notes the international oilfield service markets are \"firmly in recovery mode,\" and SLB is a \"primary beneficiary... with nearly 4x the international earnings power of its nearest  competitor.\"</li><li>In starting peer Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color=\"green\">+2.9%</font>) - the dominant player in U.S. shale services - at Buy, Snyder notes the shares are down 23% YTD after falling 46% in 2018 and sees producers starting to spend more on oil services to maintain production: \"While a long way from profitability, we think the directional move over the next 12 months is up, not down.\"</li><li>Snyder also starts Baker Hughes (<a href='https://seekingalpha.com/symbol/BKR' title='Baker Hughes Company'>BKR</a> <font color=\"green\">+1.7%</font>) and TechnipFMC (<a href='https://seekingalpha.com/symbol/FTI' title='TechnipFMC plc'>FTI</a> <font color=\"green\">+1.9%</font>) with Buy ratings.</li><li>But Snyder slaps a Sell rating on Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color=\"red\">-2.3%</font>), saying the company's \"cost structure is too high relative to the offshore rate environment and outlook.\"</li><li>RIG has used the downturn to build the world's highest spec fleet of deepwater rigs along with the industry's strongest backlog by a factor of 4x, but Snyder says the aggressive spending left a high debt load and elevated cash obligations.</li><li>SLB's average <a href=\"https://seekingalpha.com/symbol/SLB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/SLB/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Bullish, while its <a href=\"https://seekingalpha.com/symbol/SLB/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520942\" data-linked=\"Schlumberger, Halliburton set to rebound, Deutsche Bank analyst says\" data-tweet=\"$SLB $HAL $BKR - Schlumberger, Halliburton set to rebound, Deutsche Bank analyst says https://seekingalpha.com/news/3520942-schlumberger-halliburton-set-to-rebound-deutsche-bank-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3520942-schlumberger-halliburton-set-to-rebound-deutsche-bank-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520939\" data-ts=\"1574277500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520939-baml-sees-target-running-20-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML sees Target running 20% higher</a></h4><ul> <li>Bank of America Merrill Lynch ratchets up its price target on Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+13%</font>) all the way to $150 on its view the retailer's same-day delivery program is firing on all cylinders.</li> <li>The firm thinks Target's Q3 momentum will extend right into the holiday quarter as new and exclusive items offered both in-stores and online bolster demand.</li> <li>BAML says valuation on Target is compelling given that the stock trades at 15X to 16X the 2-year forward PE ratio compared to the discount retail peer average of 18X.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520745-target-plus-9-percent-smashing-quarter\" target=\"_blank\">Target +9% after smashing quarter</a> (Nov. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520939\" data-linked=\"BAML sees Target running 20% higher\" data-tweet=\"$TGT - BAML sees Target running 20% higher https://seekingalpha.com/news/3520939-baml-sees-target-running-20-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3520939-baml-sees-target-running-20-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520932\" data-ts=\"1574276654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520932-california-resources-and-ring-energy-among-energy-materials-gainers-berry-petroleum-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California Resources and Ring Energy among Energy/Materials gainers; Berry Petroleum and Camber Energy among losers</a></h4><ul><li><b>Gainers: </b>California Resources (NYSE:<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a>) <font color=\"green\">+10%</font>. Ring Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a>) <font color=\"green\">+9%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"green\">+7%</font>. Centennial Resource Development (NASDAQ:<a href='https://seekingalpha.com/symbol/CDEV' title='Centennial Resource Development, Inc.'>CDEV</a>) <font color=\"green\">+6%</font>. Dawson Geophysical (NASDAQ:<a href='https://seekingalpha.com/symbol/DWSN' title='Dawson Geophysical Company'>DWSN</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Berry Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a>) <font color=\"red\">-21%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-16%</font>.McEwen Mining (NYSE:<a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a>) <font color=\"red\">-14%</font>. SAExploration (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-13%</font>. Lightbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corporation'>LTBR</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520932\" data-linked=\"California Resources and Ring Energy among Energy/Materials gainers; Berry Petroleum and Camber Energy among losers\" data-tweet=\"$CRC $REI $CVIA - California Resources and Ring Energy among Energy/Materials gainers; Berry Petroleum and Camber Energy among losers https://seekingalpha.com/news/3520932-california-resources-and-ring-energy-among-energy-materials-gainers-berry-petroleum-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3520932-california-resources-and-ring-energy-among-energy-materials-gainers-berry-petroleum-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520911\" data-ts=\"1574273577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520911-banco-bbva-argentina-leads-financial-gainers-power-reit-and-qiwi-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banco BBVA Argentina leads financial gainers; Power REIT and Qiwi among losers</a></h4><ul><li><b>Gainers:</b> Banco BBVA Argentina (NYSE:<a href='https://seekingalpha.com/symbol/BBAR' title='Banco BBVA Argentina S.A.'>BBAR</a>) <font color=\"green\">+15%</font>. Great Elm Capital Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GEC' title='Great Elm Capital Group, Inc.'>GEC</a>) <font color=\"green\">+9%</font>. Grupo Supervielle (NYSE:<a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle S.A.'>SUPV</a>) <font color=\"green\">+8%</font>. Safehold (NYSE:<a href='https://seekingalpha.com/symbol/SAFE' title='Safehold Inc.'>SAFE</a>) <font color=\"green\">+7%</font>. Grupo Financiero Galicia (NASDAQ:<a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Puyi (NASDAQ:<a href='https://seekingalpha.com/symbol/PUYI' title='Puyi Inc.'>PUYI</a>) <font color=\"red\">-17%</font>. PagSeguro Digital (NYSE:<a href='https://seekingalpha.com/symbol/PAGS' title='PagSeguro Digital Ltd.'>PAGS</a>) <font color=\"red\">-13%</font>. LexinFintech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd.'>LX</a>) <font color=\"red\">-9%</font>. Power REIT (NYSEMKT:<a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a>) <font color=\"red\">-6%</font>. Qiwi (NASDAQ:<a href='https://seekingalpha.com/symbol/QIWI' title='Qiwi plc'>QIWI</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520911\" data-linked=\"Banco BBVA Argentina leads financial gainers; Power REIT and Qiwi among losers\" data-tweet=\"$BBAR $GEC $SUPV - Banco BBVA Argentina leads financial gainers; Power REIT and Qiwi among losers https://seekingalpha.com/news/3520911-banco-bbva-argentina-leads-financial-gainers-power-reit-and-qiwi-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520911-banco-bbva-argentina-leads-financial-gainers-power-reit-and-qiwi-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520909\" data-ts=\"1574273114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520909-house-panel-passes-bill-to-decriminalize-pot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">House panel passes bill to decriminalize pot</a></h4><ul><li>The House Judiciary Committee, controlled by Democrats, has <a href=\"https://www.marketwatch.com/story/house-judiciary-chief-nadler-says-his-panel-will-pass-bill-legalizing-marijuana-but-concedes-senate-will-take-its-own-time-2019-11-19\" target=\"_blank\">voted 24-10 in favor of a bill</a> to decriminalize marijuana on the federal level. Several Republicans on the committee backed the bill as well, dubbed the Marijuana Opportunity Reinvestment and Expungement &#40;MORE&#41; Act.</li><li>The legislation, if enacted, will also expunge prior marijuana convictions, encourage resentencing hearings for people still under supervision and establish a 5% sales tax on marijuana products aimed at funding grant programs to provide job training, legal aid and other services to people ensnared in the War on Drugs.</li><li>The MORE Act has more than 50 co-sponsors in the House.</li><li>The going will undoubtedly be slower in the GOP-controlled Senate. Democratic Senators Kamala Harris &#40;CA&#41;, Cory Booker &#40;NJ&#41; and Elizabeth Warren &#40;MA&#41; are supporters.</li><li>Selected tickers: <a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>, <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>, <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a>, <a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>, <a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>, <a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>HMLSF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520909\" data-linked=\"House panel passes bill to decriminalize pot\" data-tweet=\"$CGC $TLRY $CRON - House panel passes bill to decriminalize pot https://seekingalpha.com/news/3520909-house-panel-passes-bill-to-decriminalize-pot?source=tweet\" data-url=\"https://seekingalpha.com/news/3520909-house-panel-passes-bill-to-decriminalize-pot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>329&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520908\" data-ts=\"1574273064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520908-cornerstone-building-brands-among-industrial-gainers-mastec-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cornerstone Building Brands among industrial gainers; MasTec in losers</a></h4><ul><li><b>Gainers: </b>The Dixie Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DXYN' title='The Dixie Group, Inc.'>DXYN</a>) <font color=\"green\">+9%</font>. Loma Negra Compania (NYSE:<a href='https://seekingalpha.com/symbol/LOMA' title='Loma Negra Compañía Industrial Argentina Sociedad Anónima'>LOMA</a>) <font color=\"green\">+7%</font>. Cornerstone Building Brands (NYSE:<a href='https://seekingalpha.com/symbol/CNR' title='Cornerstone Building Brands, Inc.'>CNR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>MasTec (NYSE:<a href='https://seekingalpha.com/symbol/MTZ' title='MasTec, Inc.'>MTZ</a>) <font color=\"red\">-8%</font>. Huitao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HHT' title='Huitao Technology Co.'>HHT</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520908\" data-linked=\"Cornerstone Building Brands among industrial gainers; MasTec in losers\" data-tweet=\"$DXYN $LOMA $CNR - Cornerstone Building Brands among industrial gainers; MasTec in losers https://seekingalpha.com/news/3520908-cornerstone-building-brands-among-industrial-gainers-mastec-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520908-cornerstone-building-brands-among-industrial-gainers-mastec-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520905\" data-ts=\"1574272563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USO\" target=\"_blank\">USO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520905-crude-oil-surges-u-s-supplies-rise-less-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil surges as U.S. supplies rise less than expected</a></h4><ul><li><a href=\"https://www.marketwatch.com/story/oil-prices-bounce-higher-ahead-of-eia-crude-inventory-report-2019-11-20\" target=\"_blank\">Crude oil prices bounce back</a> in a big way after <a href=\"https://seekingalpha.com/news/3520862-oil-inventories-line-consensus\" target=\"_blank\">U.S. data</a> showed a slightly smaller than expected build in domestic inventory, rising by 1.4M barrels in the week ending Nov. 15.</li><li>WTI December futures (<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a> <font color=\"green\">+3.3%</font>) surge to highs of the day, <font color=\"green\">+3.7%</font> to $57.24/bbl, after settling below its 50-day moving average of $55.59/bbl yesterday; Brent crude <font color=\"green\">+3%</font> to $62.76/bbl.</li><li>The EIA supply numbers \"were basically in line with estimates\" but did not come in nearly as high as the 6M-barrel build <a href=\"https://seekingalpha.com/news/3520658-u-s-crude-supply-rose-nearly-6m-barrels-last-week-api-says\" target=\"_blank\">reported yesterday by the API</a>, says Tariq Zahir of Tyche Capital Advisors.</li><li>\"The weekly inventory report was more supportive of prices than it appeared at first glance,\" Again Capital's John Kilduff <a href=\"https://www.cnbc.com/2019/11/20/oil-jumps-to-high-on-day-after-inventory-data-rising-tensions-in-saudi-arabia.html\" target=\"_blank\">tells CNBC</a>. \"The overall rise in crude oil inventories was distorted by 2M barrels of oil that came out of the SPR. Inventories at the Cushing, Okla., delivery hub actually fell, markedly, by over 2M barrels. Exports of crude oil also rebounded back above 3M barrels per day.\"</li><li>The energy sector (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color=\"green\">+1.1%</font>) ranks well ahead of the S&amp;P's 11 industry sectors, but even with today's gain the group is still down nearly 2% for the week vs. a 0.2% week-to-date drop in the S&amp;P 500.</li><li>Four of the top six gainers on the S&amp;P are energy names, as <a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color=\"green\">+4.8%</font>, <a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color=\"green\">+4%</font>, <a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color=\"green\">+3.9%</font>, <a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color=\"green\">+3.8%</font>; <a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> is today's leader on the Dow Jones, <font color=\"green\">+1.1%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3x Long Crude Oil ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity Covington Trust - Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares Trust II - ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/USOU' title='USCF Funds Trust - United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares Trust II - ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520905\" data-linked=\"Crude oil surges as U.S. supplies rise less than expected\" data-tweet=\"$USO $XLE $SLB - Crude oil surges as U.S. supplies rise less than expected https://seekingalpha.com/news/3520905-crude-oil-surges-u-s-supplies-rise-less-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3520905-crude-oil-surges-u-s-supplies-rise-less-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520903\" data-ts=\"1574272217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520903-crc-cgix-xxii-and-pdd-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRC, CGIX, XXII and PDD among midday movers</a></h4><ul><li><strong>Gainers: </strong>Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) <font color=\"green\">+224%</font>.</li><li>Aravive (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a>) <font color=\"green\">+64%</font>.</li><li>Surface Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology, Inc.'>SURF</a>) <font color=\"green\">+34%</font>.</li><li>Cellectar Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>) <font color=\"green\">+28%</font>.</li><li>Kiniksa Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals, Ltd.'>KNSA</a>) <font color=\"green\">+26%</font>.</li><li>Magenta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGTA' title='Magenta Therapeutics, Inc.'>MGTA</a>) <font color=\"green\">+23%</font>.</li><li>CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics, Inc.'>CTMX</a>) <font color=\"green\">+22%</font>.</li><li>Fluent (NASDAQ:<a href='https://seekingalpha.com/symbol/FLNT' title='Fluent, Inc.'>FLNT</a>) <font color=\"green\">+20%</font>.</li><li>California Resources (NYSE:<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a>) <font color=\"green\">+18%</font>.</li><li>RAPT Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RAPT' title='RAPT Therapeutics, Inc.'>RAPT</a>) <font color=\"green\">+16%</font>.</li><li><strong>Losers: </strong>22nd Century (NYSEMKT:<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a>) <font color=\"red\">-33%</font>.</li><li>LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX Inc.'>LAIX</a>) <font color=\"red\">-30%</font>.</li><li>Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) <font color=\"red\">-30%</font>.</li><li>Professional Diversity Network (NASDAQ:<a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network, Inc.'>IPDN</a>) <font color=\"red\">-22%</font>.</li><li>Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) <font color=\"red\">-21%</font>.</li><li>Berry Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a>) <font color=\"red\">-19%</font>.</li><li>Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>) <font color=\"red\">-17%</font>.</li><li>Checkpoint Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CKPT' title='Checkpoint Therapeutics, Inc.'>CKPT</a>) <font color=\"red\">-16%</font>.</li><li>Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-14%</font>.</li><li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520903\" data-linked=\"CRC, CGIX, XXII and PDD among midday movers\" data-tweet=\"$CGIX $ARAV $SURF - CRC, CGIX, XXII and PDD among midday movers https://seekingalpha.com/news/3520903-crc-cgix-xxii-and-pdd-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520903-crc-cgix-xxii-and-pdd-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520902\" data-ts=\"1574272048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WORK\" target=\"_blank\">WORK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520902-slackplus-2_6-william-blair-notes-microsoft-overreaction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Slack +2.6% as William Blair notes Microsoft overreaction</a></h4><ul>   <li>Slack (NYSE:<a href='https://seekingalpha.com/symbol/WORK' title='Slack Technologies, Inc.'>WORK</a>) is rebounding a bit from yesterday's decline, <font color=\"green\">up 2.6%</font> with support via a reaction from bullish William Blair.</li>    <li>Shares closed <font color=\"red\">down 8.4%</font> yesterday following a report that rival Microsoft Teams grew daily active users to 20M from July's 13M.</li>    <li>That's a \"bit of an overreaction,\" says analyst Bhavan Suri. The companies' products play in a \"very large market\" that could reach 1B users; each can do well and it's far too early to declare a winner, Suri says.</li>    <li>Worries over competition will dissipate over time with continued execution and as users get more familiar with Slack, Suri says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520902\" data-linked=\"Slack +2.6% as William Blair notes Microsoft overreaction\" data-tweet=\"$WORK - Slack +2.6% as William Blair notes Microsoft overreaction https://seekingalpha.com/news/3520902-slackplus-2_6-william-blair-notes-microsoft-overreaction?source=tweet\" data-url=\"https://seekingalpha.com/news/3520902-slackplus-2_6-william-blair-notes-microsoft-overreaction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520901\" data-ts=\"1574271979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CKPT\" target=\"_blank\">CKPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520901-checkpoint-therapeutics-prices-public-offering-1_27-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Checkpoint Therapeutics prices public offering at $1.27/share</a></h4><ul><li>Checkpoint Therapeutics (<a href='https://seekingalpha.com/symbol/CKPT' title='Checkpoint Therapeutics, Inc.'>CKPT</a> <font color=\"red\">-16%</font>) <a href=\"http://seekingalpha.com/pr/17705862-checkpoint-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> its underwritten public offering of 13.4M shares at $1.27 per share; the offering is expected close by Nov. 22.</li><li>Underwriters have an option to purchase up to an additional 2.01M shares</li><li>The Company expects to raise gross proceeds of ~$17M and $19.5M assuming the full exercise of the underwriter\u2019s option</li><li>Checkpoint intends to use the proceeds to support the development of cosibelimab</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520645-checkpoint-therapeutics-14-percent-hours-equity-offering\" target=\"_blank\">Checkpoint Therapeutics down 14% after hours on equity offering</a> (Nov. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520901\" data-linked=\"Checkpoint Therapeutics prices public offering at $1.27/share\" data-tweet=\"$CKPT - Checkpoint Therapeutics prices public offering at $1.27/share https://seekingalpha.com/news/3520901-checkpoint-therapeutics-prices-public-offering-1_27-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3520901-checkpoint-therapeutics-prices-public-offering-1_27-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520900\" data-ts=\"1574271386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520900-fda-oks-alnylams-givosiran-for-ahp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Alnylam&#39;s givosiran for AHP</a></h4><ul><li>Under Priority Review status, the FDA <a href=\"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-inherited-rare-disease\" target=\"_blank\">approves </a>Alnylam Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"green\">+7.5%</font>) RNAi therapeutic givosiran, branded as Givlaari, for <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK537178/\" target=\"_blank\">acute hepatic porphyria</a> &#40;AHP&#41;.</li><li>The agency's action was February 4, 2020.</li><li>The good news has spread to RNAi players Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"green\">+3.5%</font>) and Akcea Therapeutics (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics, Inc.'>AKCA</a> <font color=\"green\">+8.7%</font>).</li><li><strong>Update</strong>: Shares up <font color=\"green\">8%</font> on resumption of trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520900\" data-linked=\"FDA OKs Alnylam&#39;s givosiran for AHP\" data-tweet=\"$ALNY $IONS $AKCA - FDA OKs Alnylam&#39;s givosiran for AHP https://seekingalpha.com/news/3520900-fda-oks-alnylams-givosiran-for-ahp?source=tweet\" data-url=\"https://seekingalpha.com/news/3520900-fda-oks-alnylams-givosiran-for-ahp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520898\" data-ts=\"1574270786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520898-gm-files-racketeering-lawsuit-against-fiat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM files racketeering lawsuit against Fiat</a></h4><ul> <li>Fiat Chrysler Automobiles (<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles N.V.'>FCAU</a> <font color='red'>-2.4%</font>) slides after General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='red'>-2.2%</font>) <a href=\"https://www.detroitnews.com/story/business/autos/general-motors/2019/11/20/general-motors-accuses-fiat-chrysler-corrupt-bargaining-united-auto-workers/4248727002/\" target=\"_blank\">files</a> a racketeering lawsuit against the automaker over alleged bribes to UAW officials.</li> <li>The lawsuit points to \"clear admissions of wrongdoing\" by Fiat executives in a continuing federal investigation into union corruption. The allegations also cover the late Sergio Marchionne's role in a conspiracy to weaken GM's bargaining position with the union.</li> <li><em>The Detroit Free Press</em> reports that GM could seek billions in unspecified damages.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520898\" data-linked=\"GM files racketeering lawsuit against Fiat\" data-tweet=\"$FCAU $GM - GM files racketeering lawsuit against Fiat https://seekingalpha.com/news/3520898-gm-files-racketeering-lawsuit-against-fiat?source=tweet\" data-url=\"https://seekingalpha.com/news/3520898-gm-files-racketeering-lawsuit-against-fiat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520896\" data-ts=\"1574270219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVYA\" target=\"_blank\">AVYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520896-avayaminus-6_1-q4-revenues-fall-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avaya -6.1% as Q4 revenues fall short</a></h4><ul>   <li>Avaya Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>) is <font color=\"red\">down 6.1%</font> after <a href=\"https://seekingalpha.com/news/3520754-avaya-holdings-eps-misses-0_32-misses-revenue\" target=\"_blank\">fiscal Q4 revenues</a> declined and missed expectations.</li>    <li>In business metrics, total contract value came to $2.4B, and in large deal activity: It marked 109 deals over $1M, 14 over $5M, and 3 over $10M.</li>    <li>Some 83% of non-GAAP revenue was Software &amp; Services; 61% of product revenue was Software. About 58% of revenue was recurring revenue.</li>    <li>Cash flow from operations came to $66M; free cash flow was $37M.</li>    <li>For Q1, it's guiding to revenue of $700M-$720M (down 3-6% in constant currency) and EBITDA of $165M-$175M with a margin of about 24%. For the full year, it expects revenue of $2.82B-$2.9B and EBITDA of $650M-$700M with a margin of 20-21%.</li>    <li><a href=\"https://seekingalpha.com/article/4308001-avaya-holdings-corp-2019-q4-results-earnings-call-presentation\" target=\"_blank\">Earnings call presentation</a></li>    <li><a href=\"https://seekingalpha.com/pr/17705232-avaya-reports-fourth-quarter-fiscal-2019-financial-results\" target=\"_blank\">Press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520896\" data-linked=\"Avaya -6.1% as Q4 revenues fall short\" data-tweet=\"$AVYA - Avaya -6.1% as Q4 revenues fall short https://seekingalpha.com/news/3520896-avayaminus-6_1-q4-revenues-fall-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3520896-avayaminus-6_1-q4-revenues-fall-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520891\" data-ts=\"1574269342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520891-alnylam-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"green\">+7.5%</font>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520891\" data-linked=\"Alnylam shares halted pending news\" data-tweet=\"$ALNY - Alnylam shares halted pending news https://seekingalpha.com/news/3520891-alnylam-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3520891-alnylam-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520889\" data-ts=\"1574269215\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520889-village-farms-international-leads-consumer-gainers-crown-crafts-only-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Village Farms International leads consumer gainers; Crown Crafts only loser</a></h4><ul><li><b>Gainers: </b>Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+11%</font>. SpringWorks Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SWTX' title='SpringWorks Therapeutics, Inc.'>SWTX</a>) <font color=\"green\">+10%</font>. Arcimoto (NASDAQ:<a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a>) <font color=\"green\">+10%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+8%</font>. HOOKIPA Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/HOOK' title='HOOKIPA Pharma Inc.'>HOOK</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Crown Crafts (NASDAQ:<a href='https://seekingalpha.com/symbol/CRWS' title='Crown Crafts, Inc.'>CRWS</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520889\" data-linked=\"Village Farms International leads consumer gainers; Crown Crafts only loser\" data-tweet=\"$VFF $SWTX $FUV - Village Farms International leads consumer gainers; Crown Crafts only loser https://seekingalpha.com/news/3520889-village-farms-international-leads-consumer-gainers-crown-crafts-only-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3520889-village-farms-international-leads-consumer-gainers-crown-crafts-only-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520888\" data-ts=\"1574268684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLDM\" target=\"_blank\">FLDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520888-fluidigm-prices-convertible-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fluidigm prices convertible debt offering</a></h4><ul><li>Fluidigm (<a href='https://seekingalpha.com/symbol/FLDM' title='Fluidigm Corporation'>FLDM</a> <font color=\"red\">-3.4%</font>) <a href=\"https://seekingalpha.com/pr/17706126-fluidigm-corporation-announces-pricing-private-offering-50-million-5_25-percent-convertible\" target=\"_blank\">prices </a>its $50M private offering of 5.25% convertible senior notes due 2024 at par. The initial conversion rate is 344.8276 common shares per $1,000 principal amount of the notes (~$2.90 per share).</li><li>Initial buyers will have a 13-day option to purchase up to an additional $5M of the notes.</li><li>Closing date is November 22.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520888\" data-linked=\"Fluidigm prices convertible debt offering\" data-tweet=\"$FLDM - Fluidigm prices convertible debt offering https://seekingalpha.com/news/3520888-fluidigm-prices-convertible-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3520888-fluidigm-prices-convertible-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520887\" data-ts=\"1574268080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SR\" target=\"_blank\">SR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520887-spire-delays-earnings-call-following-negative-court-rulings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spire delays earnings call following negative court rulings</a></h4><ul><li>Spire (<a href='https://seekingalpha.com/symbol/SR' title='Spire Inc.'>SR</a> <font color='red'>-4.4%</font>) sinks after postponing its earnings conference call scheduled for today to allow time to assess the impact of <a href=\"https://seekingalpha.com/pr/17704961-spire-postpone-earnings-conference-call\" target=\"_blank\">adverse court rulings</a> from the Missouri Western District Court of Appeals.</li><li>SR says the rulings denied its appeals of the Infrastructure System Replacement Surcharge and ordered refunds of certain amounts deemed not recoverable since 2016.</li><li>The company says it strongly disagrees with the rulings and is in the process of determining any impact of the court rulings on financial results for its just-completed FY 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520887\" data-linked=\"Spire delays earnings call following negative court rulings\" data-tweet=\"$SR - Spire delays earnings call following negative court rulings https://seekingalpha.com/news/3520887-spire-delays-earnings-call-following-negative-court-rulings?source=tweet\" data-url=\"https://seekingalpha.com/news/3520887-spire-delays-earnings-call-following-negative-court-rulings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520882\" data-ts=\"1574267113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDD\" target=\"_blank\">PDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520882-pinduoduominus-21-marketing-expense-raises-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pinduoduo -21% as marketing expense raises concerns</a></h4><ul>   <li>Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) has <font color=\"red\">slid 21.4%</font> after posting a <a href=\"https://seekingalpha.com/news/3520714-pinduoduo-eps-misses-0_13-misses-revenue\" target=\"_blank\">mixed Q3 earnings report</a> where revenue disappointed and profits missed, and expenses signaled a red flag for covering analysts.</li>    <li>Adjusted sales and marketing expenses made up a higher percentage of revenue than expected, Jefferies points out. Despite the miss, user metrics were above expectations, the firm says.</li>    <li>Average monthly active users rose 85% Y/Y to 429.6M, the company said; active buyers (for 12 months) jumped 39% to 536.3M.</li>    <li>Meanwhile, annual spending per active buyer rose 75% to 1,566.7 yuan (about $219.20).</li>    <li>Citi also called attention to the S&amp;M spending jump, \"which we believe could raise concerns about how much S&amp;M spend could further increase in 4Q19 given the intensity of pricing discount\u201d by peers.</li>    <li>Citi holds a Buy rating and raised its price target to $52 from $34, now implying 62% upside.</li>    <li><a href=\"https://seekingalpha.com/article/4307999-pinduoduo-inc-2019-q3-results-earnings-call-presentation\" target=\"_blank\">Earnings call presentation</a></li>    <li><a href=\"https://seekingalpha.com/pr/17705127-pinduoduo-announces-third-quarter-2019-unaudited-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3520882\" data-linked=\"Pinduoduo -21% as marketing expense raises concerns\" data-tweet=\"$PDD - Pinduoduo -21% as marketing expense raises concerns https://seekingalpha.com/news/3520882-pinduoduominus-21-marketing-expense-raises-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3520882-pinduoduominus-21-marketing-expense-raises-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520881\" data-ts=\"1574267017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPE\" target=\"_blank\">CPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520881-revised-callon-carrizo-merger-deal-wins-iss-support\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revised Callon-Carrizo merger deal wins ISS support</a></h4><ul><li>Proxy advisory firm Institutional Shareholder Services recommends Callon Petroleum (<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a> <font color=\"green\">+4.3%</font>) shareholders <a href=\"https://seekingalpha.com/pr/17705157-iss-recommends-callon-carrizo-shareholders-vote-transaction\" target=\"_blank\">vote in favor</a> of the Carrizo Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color=\"green\">+4.3%</font>) acquisition, after previously advising a vote against the original merger.</li><li>\"Given the material improvement in terms, along with the strategic  rationale for the merger... support FOR  the transaction is now warranted,\" ISS says.</li><li>The deal was at risk of falling apart before the companies agreed <a href=\"https://seekingalpha.com/news/3519162-callon-petroleum-lowers-bid-carrizo-oil\" target=\"_blank\">last week</a> to a reduced offer of 1.75 CPE shares for each CRZO share held, down from the previous offer of 2.05 CPE shares.</li><li>Major CPE shareholder John Paulson dropped his opposition to the deal <a href=\"https://seekingalpha.com/news/3520087-paulson-drops-opposition-callon-carrizo-merger\" target=\"_blank\">earlier this week</a> and said his hedge fund sold off half of its stake in the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520881\" data-linked=\"Revised Callon-Carrizo merger deal wins ISS support\" data-tweet=\"$CPE $CRZO - Revised Callon-Carrizo merger deal wins ISS support https://seekingalpha.com/news/3520881-revised-callon-carrizo-merger-deal-wins-iss-support?source=tweet\" data-url=\"https://seekingalpha.com/news/3520881-revised-callon-carrizo-merger-deal-wins-iss-support\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520880\" data-ts=\"1574266807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAGS\" target=\"_blank\">PAGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520880-pagseguros-focus-on-micro-merchants-sets-up-long-term-growth-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PagSeguro&#39;s focus on micro-merchants sets up long-term growth - analysts</a></h4><ul><li>PagSeguro (NYSE:<a href='https://seekingalpha.com/symbol/PAGS' title='PagSeguro Digital Ltd.'>PAGS</a>) <font color=\"red\">drops 13%</font> after Q3 results were mostly in line with preliminary earnings last month.</li><li>Total payment volume per merchant, though, slowed from Q2 and management didn't fully address the issue on the <a href=\"https://seekingalpha.com/article/4307919-pagseguro-digital-ltd-pags-ceo-ricardo-dutra-q3-2019-results-earnings-call-transcript\" target=\"_blank\">call</a>, said Evercore ISI analyst Rayna Kumar in a note to clients.</li><li>Analysts attribute that to an increase in the number of smaller merchants entering the mix, a development that should help the company in the longer-term.</li><li>Increased adoption from the low-end of the micro-merchant segment reduced average spend per merchant, Kumar wrote, and should provide a larger runway for growth.</li><li>Morgan Stanley analyst Jorge Kuri explained, \"TPV on a per-merchant basis may not grow as rapidly as it has in past quarters, but according to management, this does not signal any structural changes for the company, but rather a much larger merchant base.\"</li><li>Kuri sees an opportunity for \"out-sized share of wallet and high margins.\"</li><li>Quant rating<a href=\"https://seekingalpha.com/symbol/PAGS/ratings/quant-ratings\" target=\"_blank\"> Neutral</a>; Sell-Side average rating is <a href=\"https://seekingalpha.com/symbol/PAGS/ratings/sell-side-ratings\" target=\"_blank\">Bullish </a>(11 Very Bullish, 5 Bullish, 3 Neutral).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520822-pagseguro-slides-4_5-percent-q3-disappoints\" target=\"_blank\">PagSeguro slides 4.5% after Q3 disappoints</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520880\" data-linked=\"PagSeguro&#39;s focus on micro-merchants sets up long-term growth - analysts\" data-tweet=\"$PAGS - PagSeguro&#39;s focus on micro-merchants sets up long-term growth - analysts https://seekingalpha.com/news/3520880-pagseguros-focus-on-micro-merchants-sets-up-long-term-growth-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3520880-pagseguros-focus-on-micro-merchants-sets-up-long-term-growth-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520871\" data-ts=\"1574266211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSMT\" target=\"_blank\">OSMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520871-fda-accepts-osmotica-application-for-droopy-eyelid-drug-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Osmotica application for droopy eyelid drug; shares up 2%</a></h4><ul><li>Thinly traded micro cap Osmotica Pharmaceuticals (<a href='https://seekingalpha.com/symbol/OSMT' title='Osmotica Pharmaceuticals plc'>OSMT</a> <font color=\"green\">+2.4%</font>) is up, albeit on turnover of only 55K shares, in reaction to its <a href=\"https://seekingalpha.com/pr/17705209-vertical-pharmaceuticals-llc-osmotica-company-announces-acceptance-new-drug-application-fda\" target=\"_blank\">announcement </a>that the FDA has accepted for review subsidiary Vertical Pharmaceuticals' marketing application seeking approval to use RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) to treat <a href=\"https://eyewiki.aao.org/Blepharoptosis\" target=\"_blank\">acquired blepharoptosis</a> (droopy eyelid).</li><li>The agency's action date is July 16, 2020.</li><li>RVL-1201 is a once-daily eye drop containing oxymetazoline, a direct-acting α-adrenergic receptor agonist, believed to selectly target <a href=\"https://link.springer.com/article/10.1007/s12565-009-0043-0\" target=\"_blank\">Müller\u2019s muscle</a> that helps raise the upper eyelid.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520871\" data-linked=\"FDA accepts Osmotica application for droopy eyelid drug; shares up 2%\" data-tweet=\"$OSMT - FDA accepts Osmotica application for droopy eyelid drug; shares up 2% https://seekingalpha.com/news/3520871-fda-accepts-osmotica-application-for-droopy-eyelid-drug-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3520871-fda-accepts-osmotica-application-for-droopy-eyelid-drug-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520873\" data-ts=\"1574265798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520873-cancer-genetics-leads-healthcare-gainers-amarin-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics leads healthcare gainers; Amarin among losers</a></h4><ul><li><b>Gainers: </b>Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) <font color=\"green\">+192%</font>. Aravive (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a>) <font color=\"green\">+78%</font>. Eyenovia (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEN' title='Eyenovia, Inc.'>EYEN</a>) <font color=\"green\">+27%</font>. Cellectar Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>) <font color=\"green\">+24%</font>. Kiniksa Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals, Ltd.'>KNSA</a>) <font color=\"green\">+23%</font>.</li><li><b>Losers: </b>Checkpoint Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CKPT' title='Checkpoint Therapeutics, Inc.'>CKPT</a>) <font color=\"red\">-16%</font>. Matinas BioPharma (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) <font color=\"red\">-11%</font>. Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) <font color=\"red\">-10%</font>. DarioHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a>) <font color=\"red\">-8%</font>. Organogenesis (NASDAQ:<a href='https://seekingalpha.com/symbol/ORGO' title='Organogenesis Holdings Inc.'>ORGO</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520873\" data-linked=\"Cancer Genetics leads healthcare gainers; Amarin among losers\" data-tweet=\"$CGIX $ARAV $EYEN - Cancer Genetics leads healthcare gainers; Amarin among losers https://seekingalpha.com/news/3520873-cancer-genetics-leads-healthcare-gainers-amarin-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520873-cancer-genetics-leads-healthcare-gainers-amarin-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520865\" data-ts=\"1574264750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVX\" target=\"_blank\">CVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520865-chevron-exposure-very-modest-to-california-fracking-fight-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chevron exposure &#39;very modest&#39; to California fracking fight, analyst says</a></h4><ul><li>Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='green'>+0.4%</font>) is \"very modestly\" exposed to a potential ban on new steam-flood permits in California, Wells Fargo analyst Roger Read says in reiterating his Outperform rating and $142 price target on the stock.</li><li>Read estimates less than 5% of CVX's current global production comes from  California, and not all of it is reliant on high-pressure steam-floods.</li><li>But Berry Petroleum (<a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a> <font color='red'>-20.2%</font>) plunges to two-year lows, extending <a href=\"https://seekingalpha.com/news/3520582-california-fracking-block-punishes-crc-berry-petroleum\" target=\"_blank\">yesterday's sharp slide</a> as analysts worry over the regulatory risk to the company.</li><li>Wells, for example, <a href=\"https://thefly.com/thestreet/realmoney/index.php/BRYid2996630/BRY-Wells-Fargo-downgrades-Berry-Petroleum-cuts-price-target-to--from-\" target=\"_blank\">downgrades</a> BRY shares to Market  Perform from Outperform with a $9 price target, cut from $13, as the new rules cast doubt on the company's ability to budget, forecast and execute a stable  operational plan going forward.</li><li>BRY also is downgraded at KeyBanc, Tudor Pickering and BMO Capital.</li><li>California Resources Corp. (<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+6.2%</font>), whose shares also sank yesterday, is <a href=\"https://seekingalpha.com/news/3520768-california-resources-rebounds-berry-adds-losses-fracking-crackdown\" target=\"_blank\">rebounding</a> after saying the steamfloods it operates do not require high-pressure cyclic  steam injection and none of the rigs it currently  operates require  well stimulation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520865\" data-linked=\"Chevron exposure &#39;very modest&#39; to California fracking fight, analyst says\" data-tweet=\"$CVX $BRY $CRC - Chevron exposure &#39;very modest&#39; to California fracking fight, analyst says https://seekingalpha.com/news/3520865-chevron-exposure-very-modest-to-california-fracking-fight-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3520865-chevron-exposure-very-modest-to-california-fracking-fight-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520864\" data-ts=\"1574264727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNSA\" target=\"_blank\">KNSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520864-kiniksa-up-23-on-accelerated-review-status-for-rilonacept\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kiniksa up 23% on accelerated review status for rilonacept</a></h4><ul><li>Kiniksa Pharmaceuticals (<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals, Ltd.'>KNSA</a> <font color=\"green\">+22.6%</font>) is up on a 6x surge in volume in reaction to <a href=\"https://seekingalpha.com/pr/17705390-kiniksa-announces-breakthrough-therapy-designation-rilonacept-treatment-recurrent\" target=\"_blank\">Breakthrough Therapy status</a> in the U.S. for lead drug <a href=\"https://www.kiniksa.com/our-pipeline/rilonacept/\" target=\"_blank\">rilonacept</a> for the treatment of recurrent pericarditis.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03737110?term=kiniksa&amp;draw=2&amp;rank=5\" target=\"_blank\">RHAPSODY</a>, is ongoing with topline data expected in H2 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520864\" data-linked=\"Kiniksa up 23% on accelerated review status for rilonacept\" data-tweet=\"$KNSA - Kiniksa up 23% on accelerated review status for rilonacept https://seekingalpha.com/news/3520864-kiniksa-up-23-on-accelerated-review-status-for-rilonacept?source=tweet\" data-url=\"https://seekingalpha.com/news/3520864-kiniksa-up-23-on-accelerated-review-status-for-rilonacept\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520863\" data-ts=\"1574264304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520863-target-cant-save-all-of-retail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target can&#39;t save all of retail</a></h4><ul> <li>Retail store stocks are getting pulled in two different directions after Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+13.3%</font>) dazzled with its earnings report and guidance, while Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-14.3%</font>) disappointed.</li><li>Dollar General (<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a> <font color='green'>+2%</font>), Dollar Tree (<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a> <font color='green'>+1.2%</font>), Ollie's Bargain Outlet Holdings (<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a> <font color='green'>+1%</font>), Five Below (<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below, Inc.'>FIVE</a> <font color='green'>+2%</font>) and Costco (<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a> <font color='green'>+0.2%</font>) are riding on Target's coattails a bit, while a host of mall names are following URBN lower. Those decliners include L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-6.2%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-5.5%</font>), Nordstrom (<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom, Inc.'>JWN</a> <font color='red'>-3.4%</font>), Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch Co.'>ANF</a> <font color='red'>-4.9%</font>), Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place, Inc.'>PLCE</a> <font color='red'>-4%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color='red'>-3.3%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-2.7%</font>), Genesco (<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a> <font color='red'>-3.8%</font>), Guess (<a href='https://seekingalpha.com/symbol/GES' title='Guess&#39;, Inc.'>GES</a> <font color='red'>-2.4%</font>), Ascena Retail Group (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a> <font color='red'>-7%</font>) and American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color='red'>-3%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity Covington Trust - Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/EMTY' title='ProShares Trust - ProShares Decline of the Retail Store ETF'>EMTY</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/WANT' title='Direxion Daily Consumer Discretionary Bull 3X Shares'>WANT</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Exchange-Traded Fund Trust - Invesco Dynamic Retail ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/PASS' title='Direxion Daily Consumer Discretionary Bear 3X Shares'>PASS</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Exchange-Traded Fund VI - First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Exchange-Traded Fund Trust - John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a></li>   </ul><div class=\"tiny-share-widget\" data-id=\"3520863\" data-linked=\"Target can&#39;t save all of retail\" data-tweet=\"$TGT $URBN $DG - Target can&#39;t save all of retail https://seekingalpha.com/news/3520863-target-cant-save-all-of-retail?source=tweet\" data-url=\"https://seekingalpha.com/news/3520863-target-cant-save-all-of-retail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520862\" data-ts=\"1574263918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520862-oil-inventories-in-line-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil inventories in-line with consensus</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+1.4M</strong> barrels vs. +1.5M consensus, +2.2M last week.</li><li>Gasoline <strong>+1.8M</strong> barrels vs. +0.9M consensus, +1.9M last week.</li><li>Distillates<strong> -1.0M</strong> barrels vs. -0.7M consensus, -2.5M last week.</li><li>Futures <font color=\"green\">+0.78%</font> to $55.78.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520862\" data-linked=\"Oil inventories in-line with consensus\" data-tweet=\"$USO $OIL $UCO - Oil inventories in-line with consensus https://seekingalpha.com/news/3520862-oil-inventories-in-line-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3520862-oil-inventories-in-line-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520860\" data-ts=\"1574263761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520860-illumina-and-pacific-bio-up-on-proposed-remedies-for-merger-sign-off-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Illumina and Pacific Bio up on proposed remedies for merger sign-off in Europe</a></h4><ul><li>Pacific Biosciences of California (<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California, Inc.'>PACB</a> <font color=\"green\">+5.9%</font>) and acquirer Illumina (<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color=\"green\">+1%</font>) are both up in reaction to a <a href=\"https://assets.publishing.service.gov.uk/media/5dd5163840f0b606e951a589/Illumina_-_Remedy_proposal.pdf\" target=\"_blank\">formal response</a> from the UK's <a href=\"https://www.gov.uk/government/organisations/competition-and-markets-authority\" target=\"_blank\">Competition &amp; Markets Authority</a> &#40;CMA&#41; to its proposed remedies to concerns that their planned merger will <a href=\"https://www.gov.uk/cma-cases/illumina-inc-pacific-biosciences-of-california-inc-merger-inquiry\" target=\"_blank\">stifle competition</a>.</li><li>The CMA appears to be on board with the tie-up in consideration of the following major concessions by ILMN:</li><li>Willingness to grant a perpetual, royalty-free, irrevocable, licence to any of ILMN's or PACB's pre-closing patents and patent applications to any interested third party for use in the field of single molecule, native long read sequencing systems and associated sequencing chemistries, including pre-closing inventions that lead to patent applications within 12 months of the closing date of the merger.</li><li>To relinquish any exclusive rights in the field of single molecule, native long read sequencing systems and associated sequencing chemistries that the companies might have in relation to any in-licensed patents held as of the closing date.</li><li>To make available, prior to and as a condition to closing the merger and thereafter for as long as the patents are in force, to any interested third party undertaking a complete form license agreement for use in the field of single molecule, native long read sequencing systems and associated sequencing chemistries.</li><li>The companies' <a href=\"https://seekingalpha.com/news/3501960-pacific-biosciences-illumina-extend-merger-deadline-march-31-2020\" target=\"_blank\">target date</a> for consummating the merger is March 31, 2020.</li><li><strong>Update</strong>: An Illumina spokesperson says the the CMA has yet to formally respond to its proposed remedies, but it believes that its proposal should satisfy its concerns.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520860\" data-linked=\"Illumina and Pacific Bio up on proposed remedies for merger sign-off in Europe\" data-tweet=\"$PACB $ILMN - Illumina and Pacific Bio up on proposed remedies for merger sign-off in Europe https://seekingalpha.com/news/3520860-illumina-and-pacific-bio-up-on-proposed-remedies-for-merger-sign-off-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3520860-illumina-and-pacific-bio-up-on-proposed-remedies-for-merger-sign-off-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520851\" data-ts=\"1574261949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOW\" target=\"_blank\">LOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520851-lowes-rallies-on-strong-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lowe&#39;s rallies on strong outlook</a></h4><ul> <li>Lowe's (<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a> <font color='green'>+5.7%</font>) holds on to its gain after updating guidance further on the retailer's conference call.</li> <li>Lowe's reaffirms its expectation for operating cash flow of ~$4.5B, capex spending of ~$1.6B and free cash flow of ~$3.0B.</li> <li>The tone from Lowe's management on consumer demand was very strong, with execs noting strength across regions and categories. The read-through for investors is that the holiday quarter should be strong.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520722-lowes-eps-beats-0_06-misses-revenue\" target=\"_blank\">Lowe's EPS beats by $0.06, misses on revenue</a> (Nov. 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520730-lowes-plus-5-percent-earnings-beat-raise\" target=\"_blank\">Lowe's +5% on earnings beat and raise</a> (Nov. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520851\" data-linked=\"Lowe&#39;s rallies on strong outlook\" data-tweet=\"$LOW - Lowe&#39;s rallies on strong outlook https://seekingalpha.com/news/3520851-lowes-rallies-on-strong-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3520851-lowes-rallies-on-strong-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520848\" data-ts=\"1574261243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520848-t-faces-broad-subscriber-challenges-keybanc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AT&amp;T faces broad subscriber challenges - KeyBanc</a></h4><ul>   <li>AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"red\">-1.6%</font>) is facing challenges in subscriber businesses and hot streaming competition, KeyBanc Capital Markets says in a reiteration of its Sector-Weight view.</li>    <li>The firm points in particular to the end of <i>Game of Thrones,</i> which led to a sequential exodus in HBO subscribers (though year-over-year growth was strong).</li>    <li>The company has \"broad exposure to secularly challenged businesses,\" analyst Brandon Nispel says, also noting declining subs for AT&amp;T TV NOW and DirecTV in October. \"While video monetization remains healthy, subscriber metrics are not,\" he says.</li>    <li>HBO Max, set for a spring launch, will likely be \"nowhere near as popular\" as the freshly launched Disney Plus (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), he writes.</li>    <li>Meanwhile, AT&amp;T's valuation is at an all-time high with respect to enterprise value/EBITDA, the firm says.</li>    <li>Yesterday, the stock responded negatively as Craig Moffett <a href=\"https://seekingalpha.com/news/3520465-t-minus-2_5-percent-moffett-cuts-sell-weaker-fundamentals\" target=\"_blank\">downgraded AT&amp;T to Sell</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520848\" data-linked=\"AT&amp;T faces broad subscriber challenges - KeyBanc\" data-tweet=\"$DIS $T - AT&amp;T faces broad subscriber challenges - KeyBanc https://seekingalpha.com/news/3520848-t-faces-broad-subscriber-challenges-keybanc?source=tweet\" data-url=\"https://seekingalpha.com/news/3520848-t-faces-broad-subscriber-challenges-keybanc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>117&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520842\" data-ts=\"1574260894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGIX\" target=\"_blank\">CGIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520842-cancer-genetics-up-big-on-improved-improved-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics up big on improved improved Q3 results</a></h4><ul><li>Thinly traded nano cap Cancer Genetics (<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color=\"green\">+122.6%</font>) is up out the gate on a 10x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17705433-cancer-genetics-reports-third-quarter-2019-financial-results-provides-strategic-business\" target=\"_blank\">Q3 report</a>. Highlights:</li><li>Revenue: $2.1M (+287%).</li><li>Net income: $2.0M (+123%); EPS: $0.98 (+110%).</li><li>Completed the sale of two operating units for cash (~$9.1M), notes and future payment streams.</li><li>Management is exploring strategic alternatives with the assistance of H.C. Wainwright.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520782-cancer-genetics-reports-q3-results\" target=\"_blank\">Cancer Genetics reports Q3 results</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520842\" data-linked=\"Cancer Genetics up big on improved improved Q3 results\" data-tweet=\"$CGIX - Cancer Genetics up big on improved improved Q3 results https://seekingalpha.com/news/3520842-cancer-genetics-up-big-on-improved-improved-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3520842-cancer-genetics-up-big-on-improved-improved-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520843\" data-ts=\"1574260882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAN\" target=\"_blank\">DAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520843-oppenheimer-bullish-on-dana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer bullish on Dana</a></h4><ul> <li>Oppenheimer launches coverage on Dana (<a href='https://seekingalpha.com/symbol/DAN' title='Dana Incorporated'>DAN</a> <font color='red'>-0.7%</font>) with an Outperform rating.</li> <li>The firm says Dana's \"leverage the core\" strategy across its end-markets has substantially improved business quality over the past several years and it sees further runway to drive market outperformance and margin expansion.</li> <li>\"We have a favorable view of Dana\u2019s EV strategy given its broad portfolio of solutions, market focus and net content growth opportunities from electrification. While valuation reflects investor concerns on peakish end-markets, we believe the current share price significantly discounts Dana\u2019s cross-cycle earnings power,\" write analyst Colin Rusch and team.</li> <li>Oppenheimer's price target of $20 on Dana reps 19% upside potential and is level with the <a href=\"https://seekingalpha.com/symbol/DAN/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520843\" data-linked=\"Oppenheimer bullish on Dana\" data-tweet=\"$DAN - Oppenheimer bullish on Dana https://seekingalpha.com/news/3520843-oppenheimer-bullish-on-dana?source=tweet\" data-url=\"https://seekingalpha.com/news/3520843-oppenheimer-bullish-on-dana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520834\" data-ts=\"1574260136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MUX\" target=\"_blank\">MUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520834-mcewen-mining-prices-public-offering-1_325-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McEwen Mining prices public offering at $1.325/unit</a></h4><ul><li>McEwen Mining (NYSE:<a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a>) <font color=\"red\">-17.2%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17705599-mcewen-mining-announces-pricing-us-50-million-public-offering\" target=\"_blank\">pricing a planned public offering</a> of 37.75M common units at $1.325  each, for ~$50M in aggregate gross proceeds.</li><li>MUX grants an underwriters' option to purchase up to an  additional ~5.66M common shares and/or additional warrants  to purchase up to ~2.83M shares.</li><li>MUX has said it <a href=\"https://seekingalpha.com/news/3520646-mcewen-mining-plans-stock-offering-size-disclosed\" target=\"_blank\">plans to use the net proceeds</a> for advancing current mining  projects and exploration prospects, for additional operating capital and  for general working capital purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520834\" data-linked=\"McEwen Mining prices public offering at $1.325/unit\" data-tweet=\"$MUX - McEwen Mining prices public offering at $1.325/unit https://seekingalpha.com/news/3520834-mcewen-mining-prices-public-offering-1_325-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3520834-mcewen-mining-prices-public-offering-1_325-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520829\" data-ts=\"1574259885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520829-tgt-myov-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TGT, MYOV among premarket gainers</a></h4><ul><li>Aravive (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a>) <font color=\"green\">+212%</font> on promise of <a href=\"https://seekingalpha.com/news/3520798-aravive-rockets-263-percent-premarket-promise-lead-candidate\" target=\"_blank\">lead candidate</a>.</li><li>Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) <font color=\"green\">+203%</font> on announcing <a href=\"https://seekingalpha.com/pr/17705433-cancer-genetics-reports-third-quarter-2019-financial-results-provides-strategic-business\" target=\"_blank\">Q3 update</a>.</li><li>My Size (NASDAQ:<a href='https://seekingalpha.com/symbol/MYSZ' title='My Size, Inc.'>MYSZ</a>) <font color=\"green\">+31%</font> on <a href=\"https://seekingalpha.com/pr/17705537-mysize-launches-two-new-features-mysizeid-widget-decreases-customer-returns-31-percent-boyish\" target=\"_blank\">launching</a> two new features for the MySizeID widget.</li><li>Kiniksa Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals, Ltd.'>KNSA</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/pr/17705390-kiniksa-announces-breakthrough-therapy-designation-rilonacept-treatment-recurrent\" target=\"_blank\">BTD tag</a> for rilonacept.</li><li>Intelsat S.A. (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"green\">+15%</font> on <a href=\"https://seekingalpha.com/news/3520773-raymond-james-buys-dip-intelsat\" target=\"_blank\">analyst</a> upgrade.</li><li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3520733-target-eps-beats-0_17-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Myovant Sciences (NYSE:<a href='https://seekingalpha.com/symbol/MYOV' title='Myovant Sciences Ltd.'>MYOV</a>) <font color=\"green\">+9%</font>.</li><li>California Resources (NYSE:<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a>) <font color=\"green\">+8%</font> after no impact of California's <a href=\"https://seekingalpha.com/news/3520768-california-resources-rebounds-berry-adds-losses-fracking-crackdown\" target=\"_blank\">fracking crackdown</a>.</li><li>T2 Biosystems (NASDAQ:<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems, Inc.'>TTOO</a>) <font color=\"green\">+8%</font> after <a href=\"https://seekingalpha.com/pr/17705317-t2-biosystems-announces-granting-ce-mark-t2resistance-panel\" target=\"_blank\">T2Resistance Panel</a> CE-Mark'd.</li><li>Brainstorm Cell Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BCLI' title='Brainstorm Cell Therapeutics Inc.'>BCLI</a>) <font color=\"green\">+7%</font> on announcing publication of <a href=\"https://seekingalpha.com/pr/17705268-brainstorm-cell-therapeutics-announces-publication-nurown-als-phase-2-randomized-clinical\" target=\"_blank\">NurOwn ALS Phase 2 trial</a> data in neurology.</li><li>Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3520807-canopy-growth-6-percent-bofa-buys-dip\" target=\"_blank\">analyst</a> upgrade.</li><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) <font color=\"green\">+5%</font> on Point72 stake.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520829\" data-linked=\"TGT, MYOV among premarket gainers\" data-tweet=\"$ARAV $CGIX $MYSZ - TGT, MYOV among premarket gainers https://seekingalpha.com/news/3520829-tgt-myov-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520829-tgt-myov-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520824\" data-ts=\"1574258942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520824-cantor-sees-19-upside-in-j-and-j-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor sees 19% upside in J&amp;J in premarket analyst action</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) initiated with Outperform rating and $128 (31% upside) price target at Oppenheimer.</li><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) initiated with Underperform rating and $7 (69% downside risk) price target at Oppenheimer. <a href=\"https://seekingalpha.com/news/3520662-amarin-slips-3-percent-bearish-coverage\" target=\"_blank\">Reported yesterday.</a> Shares down <font color=\"red\">5%</font> premarket.</li><li>CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics, Inc.'>CTMX</a>) initiated with Buy rating and $16 (209% upside) price target at Guggenheim. Shares up <font color=\"green\">12% </font>premarket.</li><li>Exicure (NASDAQ:<a href='https://seekingalpha.com/symbol/XCUR' title='Exicure, Inc.'>XCUR</a>) initiated with Buy rating and $9 (246% upside) price target at Guggenheim. Shares up <font color=\"green\">11%</font> premarket.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) initiated with Overweight rating and $160 (19% upside) price target at Cantor Fitzgerald.</li><li>Mustang Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MBIO' title='Mustang Bio, Inc.'>MBIO</a>) resumed with Overweight rating and $7 (172% upside) price target at Cantor. Shares up <font color=\"green\">6% </font>premarket.</li><li>MorphoSys AG (NASDAQ:<a href='https://seekingalpha.com/symbol/MOR' title='MorphoSys AG'>MOR</a>) initiated with Buy rating and \u20ac126 (19% upside) price target at Guggenheim. Shares up <font color=\"green\">1% </font>premarket.</li><li>Phathom Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAT' title='Phathom Pharmaceuticals, Inc.'>PHAT</a>) initiated with Outperform rating at Evercore ISI.</li><li>Y-mAbs Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/YMAB' title='Y-mAbs Therapeutics, Inc.'>YMAB</a>) initiated with Buy rating and $40 (40% upside) price target at Guggenheim.</li><li>Zymeworks (NYSE:<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks Inc.'>ZYME</a>) initiated with Buy rating and $48 (25% upside) price target at Guggenheim.</li><li>Castlight Health (NYSE:<a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a>) downgraded to Hold with a $1.50 (6% upside) price target at Canaccord Genuity.</li><li>The Medicines Company (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) downgraded to In Line at Evercore ISI.</li><li>VIVO Cannabis (<a href='https://seekingalpha.com/symbol/VVCIF' title='VIVO Cannabis Inc.'>OTCQB:VVCIF</a>) downgraded to Hold at Canaccord.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520824\" data-linked=\"Cantor sees 19% upside in J&amp;J in premarket analyst action\" data-tweet=\"$ALNY $AMRN $CTMX - Cantor sees 19% upside in J&amp;J in premarket analyst action https://seekingalpha.com/news/3520824-cantor-sees-19-upside-in-j-and-j-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3520824-cantor-sees-19-upside-in-j-and-j-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520822\" data-ts=\"1574258858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAGS\" target=\"_blank\">PAGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520822-pagseguro-slides-4_5-after-q3-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PagSeguro slides 4.5% after Q3 disappoints</a></h4><ul><li>PagSeguro (NYSE:<a href='https://seekingalpha.com/symbol/PAGS' title='PagSeguro Digital Ltd.'>PAGS</a>) falls 4.5% in premarket trading after <a href=\"http://investors.pagseguro.com/Cache/1500125625.PDF?O=PDF&amp;T=&amp;Y=&amp;D=&amp;FID=1500125625&amp;iid=9282297\" target=\"_blank\">Q3 adjusted EPS</a> of R$1.18 (US$0.28) misses the average analyst estimate of R$1.20.</li><li>Increases from R$0.94 in the year-ago quarter.</li><li>Q3 total payment volume of R$29.4B rises 45% Y/Y.</li><li>Q3 total net revenue of R$1.46B, up 29% Y/Y, falls short of the R$1.86B consensus.</li><li>Q3 net income of R$342.6M increases 48% from R$231.6M a year earlier.</li><li>Q3 net margin of 23.4% improves from 20.4% in the year-ago quarter; adjusted net margin of 26.7% widens from 25.9%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520636-pagseguro-eps-misses-r-0_02-misses-revenue\" target=\"_blank\">PagSeguro EPS misses by R$0.02, misses on revenue</a> (Nov. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520822\" data-linked=\"PagSeguro slides 4.5% after Q3 disappoints\" data-tweet=\"$PAGS - PagSeguro slides 4.5% after Q3 disappoints https://seekingalpha.com/news/3520822-pagseguro-slides-4_5-after-q3-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3520822-pagseguro-slides-4_5-after-q3-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520821\" data-ts=\"1574258835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520821-pdd-urbn-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDD, URBN among premarket losers</a></h4><ul><li>Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) <font color=\"red\">-22%</font> on <a href=\"https://seekingalpha.com/news/3520714-pinduoduo-eps-misses-0_13-misses-revenue\" target=\"_blank\">Q3 earnings.</a></li><li>McEwen Mining (NYSE:<a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a>) <font color=\"red\">-17%</font> on <a href=\"https://seekingalpha.com/news/3520646-mcewen-mining-plans-stock-offering-size-disclosed\" target=\"_blank\">announcing</a> stock offering.</li><li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) <font color=\"red\">-15%</font> on <a href=\"https://seekingalpha.com/news/3520606-urban-outfitters-eps-misses-0_01-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Berry Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a>) <font color=\"red\">-8%</font> after California Gov. Newsom <a href=\"https://seekingalpha.com/news/3520582-california-fracking-block-punishes-crc-berry-petroleum\" target=\"_blank\">stops the approval</a> of new hydraulic fracturing in the state.</li><li>SAExploration Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520821\" data-linked=\"PDD, URBN among premarket losers\" data-tweet=\"$PDD $MUX $URBN - PDD, URBN among premarket losers https://seekingalpha.com/news/3520821-pdd-urbn-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3520821-pdd-urbn-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520812\" data-ts=\"1574257681\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520812-vivus-up-8-premarket-on-positive-qsymia-effect-in-binge-eating-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VIVUS up 8% premarket on positive Qsymia effect in binge-eating disorder</a></h4><ul><li>Thinly traded nano cap VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) is up <font color=\"green\">8%</font> premarket on average volume in reaction to <a href=\"https://seekingalpha.com/pr/17705315-new-clinical-data-demonstrate-vivus-qsymia-effective-reducing-binge-eating-patients-binge\" target=\"_blank\">results </a>from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02553824?term=NCT02553824&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 1 clinical trial</a> evaluating Qsymia (phentermine and topiramate extended-release) capsules CIV in patients with binge-eating disorder or <a href=\"https://www.nationaleatingdisorders.org/learn/by-eating-disorder/bulimia\" target=\"_blank\">bulimia nervosa</a> (binge eating followed by purging). The data were just published online in the <em>International Journal of Eating Disorders</em>.</li><li>22 participants were randomized to receive either Qsymia or placebo for 12 weeks. The primary endpoint was the number of objective binge-eating &#40;OBE&#41; days over four weeks.</li><li>Patients receiving Qsymia had an average of 4.2 OBE days, a decrease of 74% from baseline (16.2) compared to 13.2 OBE days for control (p&lt;0.0001).</li><li>Abstinence rates were 64% for the Qsymia group versus 9% for placebo (p&lt;0.001).</li><li>Dropout rates (9%) were the same in both arms.</li><li>Qsymia is currently approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index &#40;BMI&#41; of 30 kg/m<em><sup>2</sup></em> or greater (obese) or 27 kg/m<em><sup>2</sup></em> or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520812\" data-linked=\"VIVUS up 8% premarket on positive Qsymia effect in binge-eating disorder\" data-tweet=\"$VVUS - VIVUS up 8% premarket on positive Qsymia effect in binge-eating disorder https://seekingalpha.com/news/3520812-vivus-up-8-premarket-on-positive-qsymia-effect-in-binge-eating-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3520812-vivus-up-8-premarket-on-positive-qsymia-effect-in-binge-eating-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520810\" data-ts=\"1574257512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRRA\" target=\"_blank\">SRRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520810-sierra-oncologyplus-10-premarket-on-launching-late-stage-momentum-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sierra Oncology +10% premarket on launching late-stage Momentum trial</a></h4><ul> <li>Sierra Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a>) has <a href=\"https://seekingalpha.com/pr/17705230-sierra-oncology-launches-momentum-phase-3-clinical-trial-patients-myelofibrosis3\" target=\"_blank\">launched</a> the MOMENTUM clinical trial for patients with myelofibrosis.</li><li>The Phase 3 trial is designed to confirm the efficacy of momelotinib on myelofibrosis symptoms, transfusion independence and splenomegaly, as compared to danazol.</li><li>180 myelofibrosis patients who are symptomatic, anemic and have been treated previously with a JAK inhibitor will be enrolled.</li><li>Top-line data is anticipated in Q4 2021.</li>     <li>The primary endpoint of the trial is the Total Symptom Score response rate of momelotinib compared to danazol at Week 24.</li><li>Shares are up <font color=\"green\">10%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3520810\" data-linked=\"Sierra Oncology +10% premarket on launching late-stage Momentum trial\" data-tweet=\"$SRRA - Sierra Oncology +10% premarket on launching late-stage Momentum trial https://seekingalpha.com/news/3520810-sierra-oncologyplus-10-premarket-on-launching-late-stage-momentum-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3520810-sierra-oncologyplus-10-premarket-on-launching-late-stage-momentum-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520807\" data-ts=\"1574257238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520807-canopy-growth-up-6-bofa-buys-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth up 6% as BofA buys the dip</a></h4><ul><li>With the stock<font color=\"red\"> off some 70%</font> over the past few months, the valuation is at a minimum more \"reasonable,\" says BofA analyst Christopher Carey, upgrading Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) to Buy.</li><li>Consensus estimates look \"achievable (even beatable)\" for the first time ever, he adds.</li><li>Shares are <font color=\"green\">up 6%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520807\" data-linked=\"Canopy Growth up 6% as BofA buys the dip\" data-tweet=\"$CGC - Canopy Growth up 6% as BofA buys the dip https://seekingalpha.com/news/3520807-canopy-growth-up-6-bofa-buys-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3520807-canopy-growth-up-6-bofa-buys-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520798\" data-ts=\"1574256510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARAV\" target=\"_blank\">ARAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520798-aravive-rockets-263-premarket-on-promise-of-lead-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aravive rockets 263% premarket on promise of lead candidate</a></h4><ul><li>Thinly traded nano cap Aravive (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a>) jumps <font color=\"green\">263%</font> premarket on robust volume in reaction to <a href=\"https://seekingalpha.com/pr/17705238-aravive-reports-positive-data-supporting-relationship-avbminus-500-levels-anti-tumor-activity\" target=\"_blank\">positive data</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03639246?term=aravive&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 1b clinical trial</a> evaluating lead candidate AVB-500 in platinum-resistant ovarian cancer.</li><li>High serum levels of <a href=\"https://aravive.com/pipeline/#top\" target=\"_blank\">AVB-500</a>, what the company calls a decoy protein that starves a certain signaling pathway essential for cell migration and cancer proliferation, were \"strongly predictive\" of anti-tumor activity with statistically significant correlation to progression-free survival &#40;PFS&#41;, the primary endpoint for studies in this patient population.</li><li>Specifically, patients receiving a dose of 10 mg/kg every other week and who achieved at least the minimal level of efficacious concentration (n=17/31) experienced greater than a four-fold increase in median PFS compared to those with low exposure (n=14/31) (8.1 months vs. 1.8 months; p=0.0016) and double the response rate  (29% vs. 14%).</li><li>Patients with sufficient AVB-500 exposure also showed increases in duration of response (7.6 months vs. 3.9 months) and clinical benefit rate (responders + stable cancer) (82% vs. 43%) with significantly less risk of cancer progression (18% vs. 57%).</li></ul><div class=\"tiny-share-widget\" data-id=\"3520798\" data-linked=\"Aravive rockets 263% premarket on promise of lead candidate\" data-tweet=\"$ARAV - Aravive rockets 263% premarket on promise of lead candidate https://seekingalpha.com/news/3520798-aravive-rockets-263-premarket-on-promise-of-lead-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3520798-aravive-rockets-263-premarket-on-promise-of-lead-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520795\" data-ts=\"1574256317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVN\" target=\"_blank\">TRVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520795-trevenaplus-12-on-positive-oliceridine-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trevena +12% on positive oliceridine data</a></h4><ul> <li>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) <a href=\"https://seekingalpha.com/pr/17705277-trevena-announces-publication-results-phase-3-real-world-safety-study-oliceridine-journal\" target=\"_blank\">announces</a> results from the Phase 3 open-label safety study (ATHENA) for IV oliceridine in <em>The Journal of Pain Research</em>.</li><li>The results highlight the safety and tolerability of oliceridine in the management of moderate-to-severe acute pain in a variety of surgical/medical settings and patient populations.</li><li>768 patients were enrolled in the study. The results show that oliceridine was generally safe and well-tolerated.</li><li>Additionally, oliceridine performed consistently in the patient population, including elderly and obese patients, who are at greater risk for developing opioid-related adverse effects.</li><li>These findings suggest that oliceridine may represent a potential new treatment option where IV opioid therapy is warranted.</li><li>Shares are up <font color=\"green\">12%</font> premarket.</li>                  </ul><div class=\"tiny-share-widget\" data-id=\"3520795\" data-linked=\"Trevena +12% on positive oliceridine data\" data-tweet=\"$TRVN - Trevena +12% on positive oliceridine data https://seekingalpha.com/news/3520795-trevenaplus-12-on-positive-oliceridine-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3520795-trevenaplus-12-on-positive-oliceridine-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520786\" data-ts=\"1574255463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QIWI\" target=\"_blank\">QIWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520786-qiwiplus-4_1-after-q3-beat-and-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QIWI +4.1% after Q3 beat-and-raise</a></h4><ul><li>QIWI (NASDAQ:<a href='https://seekingalpha.com/symbol/QIWI' title='Qiwi plc'>QIWI</a>) <font color=\"green\">rises 4.1% </font>in premarket trading after Q3 earnings come in stronger than expected and year guidance is raised.</li><li>Now sees<a href=\"https://seekingalpha.com/pr/17606631-qiwi-announces-second-quarter-2019-financial-results\" target=\"_blank\"> 2019 total adjusted net revenue</a> rising 15% to 19% Y/Y compared with previous guidance of 11%-16%.</li><li>Sees 2019 adjusted net profit up 45%-55% Y/Y vs. 40%-50% in its August outlook.</li><li>Sees Payment Services segment net revenue rising 25%-29% vs. previous guidance of 23%-27%.</li><li>Reiterates Payment Services segment net profit guidance for an increase of 25%-29%.</li><li>Q3 adjusted net profit of RUB 1.89B ($29.4M), or RUB 30.30 per share (47 cents), increased from RUB 1.17B, or RUB 18.99 per share, in the year-ago quarter.</li><li>Q3 adjusted EPS of 47 cents beats the average analyst estimate of 35 cents.</li><li>Q3 revenue of RUB 5.99B ($93M) rose from RUB 5.23B; beats the consensus estimate of $90.7M.</li><li><a href=\"https://investor.qiwi.com/\" target=\"_blank\">Conference call</a> at 8:30 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520732-qiwi-plc-eps-beats-0_15-beats-revenue\" target=\"_blank\">QIWI plc EPS beats by $0.15, beats on revenue</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520786\" data-linked=\"QIWI +4.1% after Q3 beat-and-raise\" data-tweet=\"$QIWI - QIWI +4.1% after Q3 beat-and-raise https://seekingalpha.com/news/3520786-qiwiplus-4_1-after-q3-beat-and-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3520786-qiwiplus-4_1-after-q3-beat-and-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520781\" data-ts=\"1574255168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520781-salesforce-on-watch-dreamforce-event-ramps-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salesforce on watch as Dreamforce event ramps up</a></h4><ul> <li>Salesforce (NYSE:<a href='https://seekingalpha.com/symbol/CRM' title='salesforce.com, inc.'>CRM</a>) is on watch after the company updates guidance in front of annual <a href=\"https://investor.salesforce.com/events-and-presentations/event-details/2019/Annual-Investor-Day-at-Dreamforce-2019/default.aspx\" target=\"_blank\">investor day</a> event today that it calls Dreamforce.</li> <li>Salesforce expects FY20 revenue of $16.99B to $17.00B vs. $16.75B to $16.90 prior view and $16.84B consensus.</li> <li>For FY21, Salesforce sees revenue of $20.8B to $20.9B vs. $20.87B consensus. Notably, Salesforce expects to see improving organic operating efficiencies in FY21 from prior M&amp;A.</li> <li>Shares of CRM are <font color=\"red\">down 1.19%</font> premarket to $162.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520781\" data-linked=\"Salesforce on watch as Dreamforce event ramps up\" data-tweet=\"$CRM - Salesforce on watch as Dreamforce event ramps up https://seekingalpha.com/news/3520781-salesforce-on-watch-dreamforce-event-ramps-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3520781-salesforce-on-watch-dreamforce-event-ramps-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520773\" data-ts=\"1574254557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520773-raymond-james-buys-dip-in-intelsat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James buys the dip in Intelsat</a></h4><ul><li>The risk/reward on Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) is far more interesting after the stock's <font color=\"red\">75% decline</font> over the last handful of sessions, says Raymond James, upgrading to Outperform. The team's $12 price target suggests about <font color=\"green\">100% upside</font> from yesterday's close.</li><li>Shares are <font color=\"green\">up 6.1%</font> premarket to $6.46.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520773\" data-linked=\"Raymond James buys the dip in Intelsat\" data-tweet=\"$I - Raymond James buys the dip in Intelsat https://seekingalpha.com/news/3520773-raymond-james-buys-dip-in-intelsat?source=tweet\" data-url=\"https://seekingalpha.com/news/3520773-raymond-james-buys-dip-in-intelsat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520771\" data-ts=\"1574254404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACB\" target=\"_blank\">ACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520771-aurora-beefs-up-leadership-team-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurora beefs up leadership team; shares up 3% premarket</a></h4><ul> <li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) <a href=\"https://seekingalpha.com/pr/17705243-aurora-cannabis-strengthens-leadership-team-adding-chief-product-officer-chief-integration\" target=\"_blank\">promotes</a> Dr. Shane Morris, formerly Senior VP of Product Development and Regulatory Affairs to Chief Product Officer and André Jérôme, formerly Senior VP of Business Integrations to Chief Integration Officer, effective immediately.</li> <li>Dr. Morris joined Aurora in January 2018. He has led the development, regulatory oversight and market introduction for several of the Company's innovative cannabis products, including Aurora's Oral Mist, Oral Dissolve Strips, and Aurora Cloud.</li> <li>Mr. Jérôme joined Aurora in February 2018. He has led the successful integration of many of Aurora's largest business assets.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520771\" data-linked=\"Aurora beefs up leadership team; shares up 3% premarket\" data-tweet=\"$ACB - Aurora beefs up leadership team; shares up 3% premarket https://seekingalpha.com/news/3520771-aurora-beefs-up-leadership-team-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3520771-aurora-beefs-up-leadership-team-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520768\" data-ts=\"1574253411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRC\" target=\"_blank\">CRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520768-california-resources-rebounds-berry-adds-to-losses-on-fracking-crackdown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California Resources rebounds, Berry adds to losses on fracking crackdown</a></h4><ul><li>California Resources Corp. (NYSE:<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a>) <font color=\"green\">+5%</font> pre-market after saying it <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/1609253/000160925319000156/a20191119form8-k.htm\" target=\"_blank\">does not expect</a> yesterday's proposal by the California Department of Conservation to have a significant effect on its production, plans or reserves.</li><li>CRC says the steamfloods it operates do not require high-pressure cyclic steam injection as referenced in the proposal, and notes it currently operates a total of eight rigs drilling wells, none of which require well stimulation.</li><li>But Berry Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a>) <font color=\"red\">-6.7%</font> pre-market despite issuing its own statement yesterday saying the moratorium would <a href=\"https://seekingalpha.com/pr/17704685-moratorium-impact-berry-s-2019-performance\" target=\"_blank\">not impact its 2019 financial performance</a> and only potentially impacts its future thermal diatomite wells.</li><li>KeyBanc <a href=\"https://thefly.com/thestreet/realmoney/index.php/BRYid2996529/BRY-Berry-Petroleum-downgraded-to-Underweight-from-Sector-Weight-at-KeyBanc\" target=\"_blank\">downgrades</a> BRY to Underweight  from Sector Weight with a $6.50 price target, saying the new rules could result in  the loss of production volumes for the company in the near future, affecting BRY's valuation and causing its cash  flow multiple to \"derate\" until there is more clarity around the  financial impact.</li><li>CRC and BRY shares plunged a respective 26.9% and 21.5% <a href=\"https://seekingalpha.com/news/3520582-california-fracking-block-punishes-crc-berry-petroleum\" target=\"_blank\">yesterday</a> following news of California's moratorium on steam-injected oil drilling and the new review process for fracking projects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520768\" data-linked=\"California Resources rebounds, Berry adds to losses on fracking crackdown\" data-tweet=\"$CRC $BRY - California Resources rebounds, Berry adds to losses on fracking crackdown https://seekingalpha.com/news/3520768-california-resources-rebounds-berry-adds-to-losses-on-fracking-crackdown?source=tweet\" data-url=\"https://seekingalpha.com/news/3520768-california-resources-rebounds-berry-adds-to-losses-on-fracking-crackdown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520766\" data-ts=\"1574253317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAP\" target=\"_blank\">TAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520766-molson-coors-said-to-be-weighing-sale-of-european-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molson Coors said to be weighing sale of European business</a></h4><ul> <li>Evercore ISI tips that Molson Coors (NYSE:<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a>) may be interested in selling its European operations.</li> <li>Molson Coors saw a 3.4% drop in sales in Q3 for the European business and a 19% decline in pretax income.</li> <li>Shares of Molson Coors are <font color=\"green\">up 1.66%</font> premarket to $53.28.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520766\" data-linked=\"Molson Coors said to be weighing sale of European business\" data-tweet=\"$TAP - Molson Coors said to be weighing sale of European business https://seekingalpha.com/news/3520766-molson-coors-said-to-be-weighing-sale-of-european-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3520766-molson-coors-said-to-be-weighing-sale-of-european-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520761\" data-ts=\"1574252836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520761-bristol-myers-opdivo-yervoy-disappoints-in-melanoma-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers&#39; Opdivo + Yervoy disappoints in melanoma study</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) <a href=\"https://seekingalpha.com/pr/17705217-bristol-myers-squibb-announces-update-checkmate-minus-915-opdivo-nivolumab-plus-yervoy\" target=\"_blank\">announces </a>that its Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03068455?term=checkmate-915&amp;draw=2&amp;rank=1\" target=\"_blank\">CheckMate-915</a>, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to Opdivo alone for the adjuvant treatment of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma failed to achieve one of the co-primary endpoints.</li><li>A statistically significant treatment effect was not reached for the endpoint of recurrence-free survival &#40;RFS&#41; in patients with tumors expressing PD-L1 &lt;1%.</li><li>The other primary endpoint is RFS in the all-comer intent-to-treat population.</li><li>The independent Data Monitoring Committee recommended that the study continue unchanged.</li><li>Shares down <font color=\"red\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520761\" data-linked=\"Bristol-Myers&#39; Opdivo + Yervoy disappoints in melanoma study\" data-tweet=\"$BMY - Bristol-Myers&#39; Opdivo + Yervoy disappoints in melanoma study https://seekingalpha.com/news/3520761-bristol-myers-opdivo-yervoy-disappoints-in-melanoma-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3520761-bristol-myers-opdivo-yervoy-disappoints-in-melanoma-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520745\" data-ts=\"1574250693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520745-targetplus-9-after-smashing-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target +9% after smashing quarter</a></h4><ul> <li>Shares of Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) are pushing higher in early action after the retailer tops <a href=\"https://seekingalpha.com/pr/17705181-target-reports-third-quarter-2019-earnings\" target=\"_blank\">Q3</a> estimates and lifts full-year profit guidance.</li> <li>Comparable sales were up 4.5% in Q3 vs. +3.5% consensus off a 3.1% increase in traffic. Digital sales rose 31% during the quarter to account for 7.5% of all sales.</li> <li>Gross margin improved 110 bps to 29.8% of sales. Operating margin was 5.4% of sales vs. 4.6% a year ago.</li> <li>Looking ahead, Target anticipates FY20 EPS of $6.25 to $6.45 vs. $6.17 consensus and $5.90 to $6.20 prior view.</li> <li>Shares of Target are <font color=\"green\">up 9.09%</font> premarket to $120.30 (record high).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520733-target-eps-beats-0_17-beats-revenue\" target=\"_blank\">Target EPS beats by $0.17, beats on revenue</a> (Nov. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3520745\" data-linked=\"Target +9% after smashing quarter\" data-tweet=\"$TGT - Target +9% after smashing quarter https://seekingalpha.com/news/3520745-targetplus-9-after-smashing-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3520745-targetplus-9-after-smashing-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520737\" data-ts=\"1574249848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXNX\" target=\"_blank\">AXNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520737-axonics-prices-stock-offering-22\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axonics prices stock offering at $22</a></h4><ul><li>Axonics Modulation Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXNX' title='Axonics Modulation Technologies, Inc.'>AXNX</a>) <a href=\"https://seekingalpha.com/pr/17705006-axonics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> its public offering of 5.0M common shares at $22 per share. Underwriters' over-allotment is an additional ~4.6M shares offered by the company and 405K offered by selling stockholders. Closing date is November 22.</li><li>Yesterday's close was $22.99.</li></ul><div class=\"tiny-share-widget\" data-id=\"3520737\" data-linked=\"Axonics prices stock offering at $22\" data-tweet=\"$AXNX - Axonics prices stock offering at $22 https://seekingalpha.com/news/3520737-axonics-prices-stock-offering-22?source=tweet\" data-url=\"https://seekingalpha.com/news/3520737-axonics-prices-stock-offering-22\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520733\" data-ts=\"1574249576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520733-target-eps-beats-0_17-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target EPS beats by $0.17, beats on revenue</a></h4><ul><li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>): Q3 Non-GAAP EPS of $1.36 <font color=\"green\">beats by $0.17</font>; GAAP EPS of $1.37 <font color=\"green\">beats by $0.18</font>.</li><li>Revenue of $18.67B (+4.8% Y/Y) <font color=\"green\">beats by $220M</font>.</li><li>Shares <font color=\"green\">+7.35%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17705181-target-reports-third-quarter-2019-earnings\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3520733\" data-linked=\"Target EPS beats by $0.17, beats on revenue\" data-tweet=\"$TGT - Target EPS beats by $0.17, beats on revenue https://seekingalpha.com/news/3520733-target-eps-beats-0_17-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3520733-target-eps-beats-0_17-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3520730\" data-ts=\"1574249130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOW\" target=\"_blank\">LOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3520730-lowesplus-5-on-earnings-beat-and-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lowe&#39;s +5% on earnings beat and raise</a></h4><ul><li>Lowe's (NYSE:<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a>) reports comparable-store sales rose 2.2% in <a href=\"https://seekingalpha.com/pr/17705162-lowes-reports-third-quarter-sales-earnings-results\" sasource=\"qp_sum_news_12\" target=\"_blank\">Q3</a> vs. consensus of +3.2%.</li><li>Comp for the U.S. home improvement business grew 3%.</li><li>Gross margin rate up 156 bps to 32.44%.</li><li>SG&amp;A expense rate improved 126 bps to 21.69%.</li><li>Operating margin rate expanded 346 bps to to 8.96%.</li><li>Merchandise inventory +10.9% to $13.72B.</li><li>Home improvement and hardware stores -129 Y/Y to 2,004.</li><li>The company repurchased $835M of stock and paid $428M in dividends during the quarter.</li><li>The company announced the closure of 34 underperforming stores in Canada.</li><li><b>FY2019 Guidance</b>: Total sales: ~+2%; Comparable-store sales: ~+3%; Operating margin rate: +290 bps to +320 bps; Adjusted operating rate: +40 bps to +60 bps; Tax rate: ~24%; Diluted EPS: $5.35 to $5.47; Adjusted EPS: $5.63 to $5.70.</li><li>LOW <font color=\"green\">+4.9%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3520722-lowes-eps-beats-0_06-misses-revenue\" target=\"_blank\">Lowe's EPS beats by $0.06, misses on revenue</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3520730\" data-linked=\"Lowe&#39;s +5% on earnings beat and raise\" data-tweet=\"$LOW - Lowe&#39;s +5% on earnings beat and raise https://seekingalpha.com/news/3520730-lowesplus-5-on-earnings-beat-and-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3520730-lowesplus-5-on-earnings-beat-and-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}